Precision Prognostics for Cardiovascular Disease in Type 2 Diabetes: A Systematic Review and Meta-analysis

Authors

Abrar Ahmad*[1], Lee-Ling Lim[2,3,4]*, Mario Luca Morieri[5,6*], Claudia Ha-ting Tam[3,7,8]*, Feifei Cheng[9], Tinashe Chikowore[10,11], Monika Dudenhöffer-Pfeifer[1], Hugo Fitipaldi[1], Chuiguo Huang[3,7,8], Sarah Kanbour[12], Sudipa Sarkar[13], Robert Wilhelm Koivula[14], Ayesha A. Motala[15], Sok Cin Tye[16,17], Gechang Yu[3,7,8], Yingchai Zhang[3,7,8], Michele Provenzano[18], Diana Sherifali[19], Russel de Souza[20], Deirdre Kay Tobias[21], Maria F. Gomez[1,22]**, Ronald C.W. Ma[3,7,8]**, Nestoras Mathioudakis[13]**

*co-first authors (contributed equally to this work), **senior authors (supervised all aspects of this work)

[1] Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Malmö, Sweden

[2] Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

[3] Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China

[4] Asia Diabetes Foundation, Hong Kong SAR

[5] Metabolic Disease Unit, University Hospital of Padova, Padova, Italy

[6] Department of Medicine, University of Padova, Padova, Italy

[7] Laboratory for Molecular Epidemiology in Diabetes, Li Ka Shing Insttiute of Health Sciences, The Chinese University of Hong Kong

[8] Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong

[9] Health Management Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China

[10] MRC/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

[11] Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

[12] AMAN Hospital, Doha, Qatar

[13] Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

[14] Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, United Kingdom

[15] Department of Diabetes and Endocrinology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
[16] Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, the Netherlands
[17] Sections on Genetics and Epidemiology, Joslin Diabetes Center, Harvard Medical School
[18] Nephrology, Dialysis and Renal Transplant Unit, IRCCS—Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, Italy
[19] Heather M. Arthur Population Health Research Institute, McMaster University, Ontario, Canada[20] Faculty of Health Sciences, McMaster University, Ontario, Canada
[21] Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
[22] Faculty of Health, Aarhus University, Denmark

Corresponding authors:
Maria F. Gomez, PhD
Professor
Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Malmö, Sweden
maria.gomez@med.lu.se

Ronald C. W. Ma, FRCP
Professor
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong
rcwma@cuhk.edu.hk

Nestoras Mathioudakis, MD MHS
Associate Professor of Medicine
Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland USA
nmathio1@jh.edu

Word Count: 6,204
Tables/Figures: 2 Tables; 8 Figures

Abstract

Background

Precision medicine has the potential to improve cardiovascular disease (CVD) risk prediction in individuals with type 2 diabetes (T2D).

Methods

We conducted a systematic review and meta-analysis of longitudinal studies to identify potentially novel prognostic factors that could improve CVD risk prediction in T2D. Out of 9380 studies identified, 416 studies met inclusion criteria. Outcomes were reported for 321 biomarker studies, 48 genetic marker studies, and 47 risk score/model studies.

Out of all evaluated biomarkers, only 13 showed improvement in prediction performance. Results of pooled meta-analyses, non-pooled analyses, and assessments of improvement in prediction performance and risk of bias, yielded the highest predictive utility for N-terminal pro b-type natriuretic peptide (NT-proBNP) (high-evidence), troponin-T (TnT) (moderate-evidence), triglyceride-glucose (TyG) index (moderate-evidence), Genetic Risk Score for Coronary Heart Disease (GRS-CHD) (moderate-evidence); moderate predictive utility for coronary computed tomography angiography (low-evidence), single-photon emission computed tomography (low-evidence), pulse wave velocity (moderate-evidence); and low predictive utility for C-reactive protein (moderate-evidence), coronary artery calcium score (low-evidence), galectin-3 (low-evidence), troponin-I (low-evidence), carotid plaque (low-evidence), and growth differentiation factor-15 (low-evidence). Risk scores showed modest discrimination on internal validation, with lower performance on external validation.

Conclusions

Despite high interest in this topic, very few studies conducted rigorous analyses to demonstrate incremental predictive utility beyond established CVD risk factors for T2D. The most promising markers identified were NT-proBNP, TnT, TyG and GRS-CHD, with the highest strength of evidence for NT-proBNP. Further research is needed to determine their clinical utility in risk stratification and management of CVD in T2D.

Plain Language Summary

Patients with T2D are at high risk for CVD but predicting who will experience a cardiac event is challenging. Current risk tools and prognostic factors, such as laboratory tests, may not accurately predict risk in different patient populations. There is a need for personalized risk prediction tools to identify patients more accurately so that CVD prevention can be targeted to those who need it most. This study examined novel biomarkers, genetic markers, and risk scores on the prediction of CVD in individuals with T2D. We found that four laboratory markers and a genetic risk score for CHD had high predictive utility beyond traditional CVD risk factors and that risk scores had modest predictive utility when tested in diverse populations, but more studies are needed to determine their usefulness in clinical practice. The highest strength of evidence was observed for NT-proBNP, a laboratory test currently used to monitor patients with heart failure but not currently used in clinical practice for the purpose of CVD prediction in T2D.

Introduction

Individuals with type 2 diabetes (T2D) have a 2-5-fold higher risk of developing cardiovascular disease (CVD) compared to those without T2D, making T2D a "coronary heart disease" risk equivalent.[1] This risk is particularly concerning given the high prevalence of diabetes worldwide and the aging population. Currently, more than 500 million individuals worldwide are affected by this chronic disease, resulting in significant human and economic costs.[2,3] Accurate individual risk assessment is, therefore, crucial to identify those who may benefit the most from treatment interventions aimed at lowering CVD risk.

However, predicting CVD risk in those with T2D remains a challenge, and existing risk algorithms, such as the UK Prospective Diabetes Study (UKPDS) Risk Engine and Framingham Risk Score (FRS), have shown only modest predictive value in external validation studies.[4-6] Thus, it is essential to develop readily available and cost-effective measures that can accurately identify individuals with a higher absolute risk of developing CVD beyond the risk estimated from established risk factors. Precision medicine provides a promising approach to optimize risk prediction by integrating multidimensional data (i.e., genetic, clinical, sociodemographic), accounting for individual differences.[7]

Recognizing the potential value of precision medicine in improving diabetes prevention and care, the Precision Medicine in Diabetes Initiative (PMDI) was established in 2018 by the American Diabetes Association (ADA) in partnership with the European Association for the Study of Diabetes (EASD) and is led by global leaders in precision diabetes medicine.[8] This Systematic Review is written on behalf of the ADA/EASD PMDI as part of a comprehensive evidence evaluation in support of the 2nd International Consensus Report on Precision Diabetes Medicine.[9] As part of this broader initiative, we conducted a systematic review and meta-analysis addressing precision prognosis for CVD outcomes. Although precision prognosis is of value for any diabetes complication, we selected CVD as the outcome of interest in this review given that it is associated with the greatest morbidity and mortality.[10,11]

Although previous systematic reviews have been conducted on the prediction of cardiovascular disease risk using traditional and non-traditional risk factors, including risk scores and genetic markers, in the general population,[12-26] our review focused on patients with T2D, a population at higher risk for CVD events. Our review sought to answer two essential questions: (1) Which novel markers predict CVD in people with T2D? (2) Is there any evidence that these markers enhance risk prediction beyond current practice? Addressing these questions may inform the development of more effective strategies for detecting and predicting CVD in individuals with T2D, ultimately leading to improved management and prevention of this complication.

In summary, using a stringent study selection process to identify the most promising prognostic factors, this systematic review and meta-analysis found four prognostic factors with high predictive utility (with strength of evidence ranging from moderate to high), three prognostic factors with moderate predictive utility (with strength of evidence ranging from low to moderate) and six prognostic factors with low predictive utility (with strength of evidence ranging from low to moderate). Risk scores showed modest discrimination on internal validation, with lower performance on external validation particularly when tested in cohorts that differed from the derivation population.

Methods

We adhered to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline in conducting this study (Figure 1).[27] Before conducting the search, the proposed systematic review and meta-analysis was registered on PROSPERO (Registration number: CRD42021262843).

Inclusion and Exclusion Criteria

This review included longitudinal studies (prospective or retrospective cohorts, including secondary analyses of cohorts from randomized controlled trials) of subjects with T2D (youth-onset and adult-onset). Inclusion criteria included observational studies published from 1990 onwards that reported on the association between a prognostic factor or risk score and one or more CVD outcomes among subjects with T2D. Exclusion criteria included cross-sectional

studies, studies utilizing surrogate endpoints for cardiovascular (CVD) outcomes such as carotid intima-media thickness, endothelial dysfunction, and arterial stiffness, and studies including only subjects with pre-diabetes or only subjects with type 1 diabetes. Studies with mixed populations of diabetes were included only if results were reported separately for subjects with T2D. Supplemental Table 1 summarizes the Participant Intervention Comparison Outcomes and Studies (PICOS) framework.

Outcomes

Only studies reporting outcomes on fatal or non-fatal coronary heart disease (CHD) and/or cardiovascular mortality (either alone or as individual component of composite outcomes) were included. We used a broad definition of CHD including any outcomes defined by terms such as myocardial infarction, ischemic heart events, cardiac events, coronary artery disease, and major cardiovascular events.

Search Strategy

We conducted a comprehensive search on Medline and Embase of studies published from January 1990 to March 2021 using relevant keywords and MeSH (Medical Subject Headings) terms pertaining to T2D and CVD (see Supplemental Text). In addition, we searched the reference lists of eligible studies and systematic reviews to identify any further relevant studies. The search strategy was designed by a multi-professional team of researchers with expertise in precision medicine, clinical diabetes, cardiovascular disease, biomarker development and evaluation, genetic markers, and predictive analytics, supported by two librarians with expertise in conducting systematic reviews and meta-analyses. References identified by database searchers were exported to EndNote (Clarivate Analytics) and imported to Covidence, where studies were assessed for eligibility. After the removal of duplicates, 14 authors participated in screening each title/abstract, and full-text articles were obtained if abstracts were considered eligible by at least one author. Each full-text article was assessed independently by two authors (among 12 total authors) for inclusion in this systematic review and meta-analysis, and disagreements were resolved by consensus.

Data extraction

All data were extracted and coded by one author and reviewed by a second author to ensure data accuracy. Eight authors participated in the data extraction process (AA, CT, LL, MG, MM, NM, RM, SK). The following data were extracted from each article using a standardized data form in Covidence and Excel data tables: *study characteristics* (country or countries of the study population, study start and end year, study design, inclusion/exclusion criteria, study setting, data sources), *participant characteristics* (years of follow-up, follow-up duration, total number of participants, race/ethnicity/ancestry, and baseline characteristics), *prognostic factor(s) characteristics* (name, prognostic factor type, units of measurement, units and cut-offs in regression analyses, transformation methods, effect measures [hazard ratio, odds ratio, c-statistic, net reclassification index (NRI), integrated discrimination index (IDI), etc.] and 95% confidence intervals, adjusted covariates), and *outcomes* (CVD outcome definition, number of events and non-events), and validation methods. For genetic markers, we collected risk variants, risk alleles, and closest gene (locus). For continuous variables, we collected mean and standard deviation or median and interquartile range, as reported in the study. Furthermore, data were collected to evaluate the *risk of biases* in each study as summarized in Supplemental Table 2 and described in the quality assessment paragraph.

During data extraction, studies were classified into three categories based on the primary type of prognostic factors reported, namely biomarkers, genetic markers, and risk scores. Candidate biomarkers were broadly defined as non-genetic laboratory tests, clinical conditions, socio-demographics, vital signs, diagnostic procedures, and imaging tests. Candidate genetic markers included specific DNA sequences or variations, such as single nucleotide polymorphisms (SNPs), restriction fragment length polymorphisms (RFLP), or short tandem repeats (STR). Risk scores were defined as prediction models, algorithms, risk engines, or calculated risk tools that estimated the overall probability of CVD event or category of CVD risk based on a set of risk factors. When multiple genetic variants were combined to predict risk (using SNPs), the study was classified as a genetic marker (i.e., genetic risk score) rather than a risk score.

The objective of this study was to identify prognostic factors that may refine CVD risk prediction beyond already known risk factors. Therefore, we excluded from the analysis those

studies that evaluated biomarkers already established as CVD risk factors (Supplemental Table 3), such as smoking, hypertension, microalbuminuria, BMI, and dyslipidemia, as defined in the 2021 European Society of Cardiology (ESC) guidelines on cardiovascular disease prevention in clinical practice.[27,28] However, we considered including biomarkers that evaluated a novel variation of an established CVD risk factor, such as HbA1c variability compared to a single time-point measurement.

The strength and quality of evidence in observational prognostic studies depend on how well the confounding variables between the prognostic factor and the outcome are accounted for. To be considered a novel risk marker, a biomarker must improve risk prediction beyond traditional markers. [27] Thus, we began by excluding all studies that did not adjust for any CVD risk factors. The quality of the statistical models for adjusting confounding factors was assessed in the next section.

Quality Assessment

We used a modified Newcastle-Ottowa Scale to assess quality and risk of biases. The scale assesses studies based on six domains, including representativeness of the exposed and non-exposed cohorts, ascertainment of exposure and outcome, and adequacy of study follow-up for primary and secondary CVD events, as well as adequacy of cohort follow-up.[29] Two authors assessed study quality independently, and any disagreements were resolved by a third author. For biomarker studies, we evaluated statistical model appropriateness based on the number of covariates and established CVD risk factors. Each study was given a score for each domain and an overall quality evaluation was determined by adding up these scores. The range of scores for non-genetic biomarkers was 2 to 28, and for genetic biomarkers and risk scores, it was 2 to 18. We reported the overall risk of bias based on the distribution of scores in each prognostic factor category. Studies in the top tertile were considered to have low risk of bias, those in the second tertile were considered to have medium risk of bias, and those in the lowest tertile were considered to have high risk of bias. The score of each domain was also classified as low, medium, or high risk of bias for graphical purposes, as clarified in Supplemental Table 2.

Statistical Analysis

We collected fully adjusted effect measures (HR, RR, OR c-statistic) and their corresponding 95% CIs reported in the original articles. When studies reported multiple multivariate-adjusted effect measures, we used the estimate from the most fully adjusted model. For studies reporting event rates without an effect measure, we calculated the odds ratio using two-by-two contingency tables and chi-square tests. In the meta-analysis, we used a random-effects model to pool the effect estimates, only if the heterogeneity test was statistically significant. We calculated summary HRs or ORs with 95% CIs for each biomarker or genetic marker and assessed heterogeneity between studies using the Cochran's Q statistic (p <0.1) and/or the I^2 index >75%. Due to the limited number of studies per prognostic factor, subgroup analyses by population characteristics or outcomes were not possible. We performed sensitivity analyses by excluding studies with high risk of bias. As the number of studies per prognostic factor was always less than 10, we were unable to assess publication bias using funnel plots. We used R, version 4.2.3 (R Project for Statistical Computing), with the "meta", "metafor", and "forestplot" packages for all analyses.[30] Two-sided statistical tests were used with a significance threshold of <0.05.

Strength of the Evidence

We considered aspects of the GRADE approach [31] and the JBI critical appraisal tools [32] in grading the strength of evidence for individual biomarkers and genetic markers/risk scores in this review. We applied relevant GRADE criteria, including indirectness, inconsistency, and imprecision, throughout the study. Since we only included studies that involved patients with T2D and a "hard" clinical CVD outcome, the evidence is considered direct by definition. We analyzed the results from T2D patients with and without baseline CVD and specified all relevant CVD outcomes to assess the applicability of individual biomarkers in specific populations and outcomes. To ensure robustness and validity of our findings, we established strict eligibility criteria, including the exclusion of studies that did not adjust for established CVD risk factors. Furthermore, we scored studies based on the adequacy of adjustment for covariates, including

the total number of covariates and established CVD risk factors, in accordance with the JBI criterion for statistical adjustment of confounders.

We used the American Heart Association scientific consensus report for stepwise evaluation of novel markers for CVD risk[33] to identify promising biomarkers and genetic markers based on their strength of evidence progressing from measures of association, discrimination, improvement in discrimination, net reclassification index (NRI) or integrated discrimination index (IDI). For biomarkers and genetic markers, we progressed from those with significant adjusted association in at least one study to those with net positive number of studies showing significant association in a consistent direction. We identified biomarkers that improved prediction performance when added to established models, based on improvement in at least one of c-statistic, NRI, or IDI, and further narrowed down the list to those with improvement in all three indicators.

Accordingly, for each of the prognostic factors that passed our evidence-based screening criteria, predictive utility was classified as *high* (3 points), *moderate* (2 points), or *low* (<2 points) based on three criteria: number of studies with all three performance indicators satisfied (1 point if >0 studies, 0 points if 0 studies), number of pooled meta-analyses showing significant association (1 point if >0, 0 points if 0 studies), non-pooled analysis showing ≥75% of studies had a significant association (1 point if yes, 0 points if no). Strength of Evidence was classified as *high* (4 points), *moderate* (2 or 3 points), or *low* (<2 points) based on four criteria: at least one meta-analysis was conducted regardless of outcome (1 point if yes, 0 points if no), exclusion of high risk of bias studies did not alter inferences from meta-analyses (1 point if unaltered, 0 points if altered), exclusion of high risk of bias studies did not alter inferences from non-pooled analyses (1 point if unaltered, 0 points if altered), and consistencies in the definition of the prognostic marker used in analyses (1 point if yes, 0 points if no).

For the risk scores, we provide a complete assessment of risk of bias and pooled c-statistics; however, we decided not to conduct a corresponding stepwise approach to evidence grading as explained above for biomarkers/genetic markers due to the complexity in verifying specifications

of each model over time and across comparisons. Inferences from the risk score results are here meant to guide future work that would permit analysis to handle this complexity.

Results

Study selection and characteristics

Out of 9380 studies identified from the search for abstract screening, 615 articles were selected for full-text review, and finally, 416 articles were considered appropriate for inclusion in the analysis. [34-293,294-449] Outcomes were reported for 321 biomarker studies, 48 genetic marker studies, and 47 risk score/model studies, as shown in Supplemental Tables 4, 5, and 6. Figures 1 and 2 provide an overview of the screening and selection process.

Predominant ancestry in the studied populations were European (57.1%), East Asian (19.7%), South Asian (5.5%) and Hispanic or Latin American (4.2%). Geographically, the United States, United Kingdom, China, Japan, and Italy were the top five dominating countries with regards to origin of study participants and author affiliation in the included studies. Figure 3 and online interactive figures (https://hugofitipaldi.shinyapps.io/T2D_prognostic/) [login username: login: groupaccess; password: QUO9Q8cC2ULdg8n-E^XZE; access information to be removed after acceptance] offer a detailed breakdown of ethnic and geographic distributions.

CVD Outcomes

There was significant heterogeneity in the CVD outcomes evaluated across the analyzed studies (see Supplemental Figure 1). The most frequently reported outcomes were coronary heart disease, cardiovascular mortality, and stroke, either individually or combined. We classified primary prevention as the prediction of CVD in individuals without a history of the disease, secondary prevention as the prediction of recurrent CVD events or CVD progression in those already diagnosed with the disease, and mixed populations as a combination of both primary and secondary prevention.

Biomarkers

Among 416 included studies, 321 (77.2%), 48 (11.5%), and 47 (11.2%) were studies of non-genetic biomarkers, genetic biomarkers, and non-genetic risk scores, respectively. Among the

321 studies of non-genetic biomarkers, 70 (21.8%) evaluated established CVD risk factors and were excluded, while 30 studies (9.3%) were included because they used a novel approach (e.g., variability, setting) for an established risk factor (Figure 2). Further, three studies did not adjust for any CVD risk factors and were excluded, leaving 218 studies consisting of 195 unique biomarkers in the analysis.

Among these 195 analyzed biomarkers, 134 (69%) had a significant adjusted association for predicting CVD, based on a net positive number of studies (Figure 4A and Supplemental Table 7). Out of these, 12 (9%) showed improvement in c-statistic, NRI, or IDI in *more than one study*: N-terminal pro b-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), troponin T (TnT), coronary artery calcium score (CACS), coronary computed tomography angiography (CCTA), single-photon emission computed tomography (SPECT) scintigraphy, pulse wave velocity (PWV), galectin-3 (Gal-3), troponin I (TnI), carotid plaque, growth differentiation factor-15 (GDF-15), and triglyceride-glucose (TyG) index. The following biomarkers showed prediction performance but in *only one study*: SPECT, TnI, TyG, 25-hydroxyvitamin D, poly (ADP-ribose) polymerase (PARP), and interleukin-6 (IL-6).

Biomarkers with *all three* prediction performance indicators satisfied in *more than one study* were NT-proBNP, TnT, and CCTA, with results summarized in Table 1. For NT-proBNP, 5 studies reported improvement in c-statistics ranging from 0.01 to 0.07, significant increase in NRI ranging from 0.04 to 0.50, and significant IDI ranging from 0.012 to 0.48 (in four studies). For TnT, 3 studies reported improvement in c-statistics ranging from 0.02 to 0.10, significant NRI ranging from 0.150 to 0.44, and IDI ranging from 0.03 to 0.05. For CCTA, 3 studies reported improvement in c-statistics ranging from 0.08 to 0.35, with one study reporting statistically significant improvements in NRI of 0.55 and IDI of 0.046. Of these three biomarkers, NT-proBNP showed the strongest incremental predictive value based on the magnitude of these indicators.

Forest plots in Figure 5A show the HRs for 11 studies evaluating NT-proBNP, conducted in heterogeneous populations (2 primary, 5 mixed, 4 secondary), outcomes, units in regression analyses (i.e., SD, SD of log), and laboratory units (ng/L, pg/mL). Nonetheless, all studies

except one showed a significant association for CVD outcome. Remarkably, 8 out of 11 (73%) studies had low risk of bias. Figure 6A and Supplemental Figures 2A and 2B show the meta-analysis of NT-proBNP as a continuous variable per logarithmic and per 1 SD unit increase, confirming the highly significant association with CVD (pooled HR 1.53, 95% CI 1.26-1.85 per log increase; pooled HR 1.59, 95% CI 1.27-1.99 per SD increase) after accounting for heterogeneity with the random effects models (I^2 90.0% and I^2 83%, respectively).

Forest plots in Figure 5B show the HRs for 8 studies evaluating TnT, conducted primarily for mixed or secondary populations with variable CVD outcomes. Studies differed with respect to cut-offs and categories for TnT, units of measurement (ng/ml, ng/L) and analysis (per log, per 1 SD log). Among these studies, all but one showed a positive association. Notably, the study by Lepojarvi 2016 was an outlier in its magnitude of effect and confidence intervals. Overall, for TnT, study quality was good with 6 out of 8 (75%) being low risk of bias. [229] A significant association for TnT was observed in studies where the biomarker was evaluated as a continuous variable per 1 log increase with pooled HR 1.64 (95% CI 1.23, 2.18) and I^2 59% (Figure 6B and Supplemental Figure 2C); similarly, when treated as a binary or categorical variable, the pooled HR was 2.64 (95% CI 1.03, 6.72) with I^2=95.9% (Figure 6B and Supplemental Figure 2D). However, when treated as a continuous variable per 1 SD, there was no association observed in a random effects model (Figure 6B and Supplemental Figure 2E).

Forest plots in Figure 5C show the HRs for 5 studies evaluating CCTA conducted primarily for primary CVD prevention with variable CVD outcomes. Studies differed significantly with respect to CCTA definition of subclinical or clinical CHD. All 5 studies showed a significant association; however, 2 of the 5 studies (40%) had a high risk of bias.

Apart from these three biomarkers, SPECT, TnI, TyG, 25-hydroxyvitamin D, poly(ADP-ribose) polymerase (PARP), and interleukin-6 (IL-6) showed prediction performance in *all three* performance indicators but in *only one study*. Forest plots for the remaining 9 biomarkers that showed improvement in *at least one* performance indicator in *more than one study* (CACS, carotid plaque, CRP, gal-3, GDF-15, PWV, SPECT scintigraphy, TnI, and TyG are shown in Supplemental Figure 3. Again, there was substantial heterogeneity with respect to study

populations, outcomes, and units of analysis for these biomarkers. Biomarkers showing positive association in at least 75% of studies included CACS, carotid plaque, gal-3, PWV, SPECT scintigraphy, TnI, and TyG. While CRP did not meet the threshold of 75% of studies showing an association, when meta-analyzed as a binary or categorical variable, it showed a significant pooled association; PWV and TyG also demonstrated significant association in pooled analysis (Supplemental Figure 4).

Genetic markers

Among the 48 genetic studies analyzed (Supplemental Table 5), 79 genetic biomarkers were examined for their association with incident CVD events (Supplemental Table 8), mainly in populations of European (65%) or Asian (26%) ancestries, with a scarce representation of populations of other ancestries (e.g. African 12% or Hispanic 3%), with 12% of associations being tested in mixed populations. Most of the studies (70 out of 79) used single variants as distinct genetic biomarkers (exposure), while 9 studies used a combination of different SNPs into genetic risk scores (GRS) as the exposure. Remarkably, most of these exposures were tested only in one study, and external validation was performed in only 4 out of 48 studies, with only one study using a longitudinal cohort as a validation set, i.e. GRS for CHD. Overall, among the 79 genetic biomarkers, 33 (41.8%) had *at least one* study showing significant association, out of which 29 had a net positive number of studies showing significant association. Out of these 29 genetic biomarkers, two were tested in *more than one* study (rs10911021 on *GLUL*, GRS for CHD [GRS-CHD]), one had improvement in *any* performance indicator in a single study (ε4 in *APOE*), and one had improvement in *all three* performance indicators in a single study (GRS-CHD) (Figure 4B).

Notably, the rs10911021 variant in *GLUL* was the only single variant that showed an association with CVD in several studies. This variant was initially identified in T2D patients using a genome-wide approach and subsequently confirmed for its association with CVD in selected populations from two additional studies. For GRS-CHD, four separate studies investigated the combination of up to 204 CHD variants from 160 distinct loci derived from the general population. These studies had distinct but overlapping and increasing numbers of loci and variants tested in more recent investigations. The most recently performed GRSs were externally

validated and demonstrated significant improvements in CVD risk reclassification (cNRI) as well as notable enhancements of 8% in relative IDI (rIDI). However, these findings were identified in subjects of European ancestry and ancestry-specific analyses showed consistency in Asian subjects but not in other ancestral backgrounds. Forest plots for variants located on the GRS-CHD and *GLUL* are shown in Figure 7, while their meta-analyses can be found in Supplemental Figure 5.

Risk scores/models

Forty-seven studies reported results of CVD risk scores (Supplemental Tables 6 and 9). Among these, 16 and 19 unique risk scores were reported in internal and external validation analyses, respectively. Figure 8A shows a meta-analysis from 14 internal validation studies (18 analyses), with a pooled c-statistic of 0.70 (95% CI 0.68-0.72) and high heterogeneity (I^2= 97.6%). Most risk scores were developed in the United States, Europe, and East Asia and 61.1% of the internal validation studies had a high risk of bias. Figure 8B shows a meta-analysis of 50 external validation analyses from 19 unique risk scores, with pooled c-statistic of 0.68 (95% CI 0.67-0.69) and high heterogeneity (I^2=97.18%). Notably, 28% of the external validation analyses had a high risk of bias. Model performance tended to decline when validated in countries that differed from the development cohort (Supplemental Figure 7). For example, the FDS study achieved high c-statistics (>0.80) when validated in an Australian cohort, but lower ones (0.58-0.69) when tested in European countries. In line with previous studies [5,6,389], discrimination for the UKPDS and FRS was generally poor on external validation. Most prediction models focused on baseline characteristics and did not account for time-varying factors that may modify CVD risk (e.g., statin, SGLT-2i, GLP-1 RA). An exception was the BRAVO risk engine, published in 2020 and validated in trials of SGLT-2i patients, showing that this risk engine effectively predicted CV health benefits through improvements in common clinical measures (e.g., A1C, SBP, and BMI). [345]

Supplemental Figure 8A and 8B provide a histogram of the total number of adjusted covariates and number of adjusted CVD risk factors in each of the studies, respectively. Supplemental

Figure 9 is a network figure representing the connections of the adjusted covariates in the 416 included studies.

Sensitivity Analyses

The results of sensitivity analyses excluding studies with high risk of bias from meta-analyses of biomarkers, genetic risk score, risk scores (internal validation), and risk scores (external validation), respectively, are shown in Supplemental Figures 10, 11, 12, and 13.

Synthesis

Table 2 provides a summary of findings of the most promising biomarkers and genetic markers/scores for precision prognosis of CVD in T2D, along with our conclusions regarding their predictive utility and strength of evidence. The highest predictive utility was observed for NT-proBNP (high-evidence), TnT (moderate-evidence), TyG (high-evidence), and GRS-CHD (moderate-evidence). Prognostic factors with moderate predictive utility were CCTA (low-evidence), SPECT scintigraphy (low-evidence), and PWV (moderate-evidence). Prognostic factors with low predictive utility included CRP (moderate-evidence), CACS (low-evidence), Gal-3 (low-evidence), TnI (low-evidence), carotid plaque (low-evidence), and GDF-15 (low-evidence). Supplemental Figures 6A, 6B, and 6C provide the quality assessment for the included biomarker, genetic marker, and risk score studies, respectively.

Discussion

Our systematic review of prognostic markers for cardiovascular endpoints in individuals with T2D has revealed several novel findings. First, among the numerous studies that investigated the prognostic significance of risk markers for subsequent cardiovascular events, only a few of them have been consistently demonstrated to be significantly associated with cardiovascular risk. Namely, NT-proBNP, TnT, TyG, and GRS-CHD demonstrated the highest predictive utility, with NT-proBNP demonstrating the strongest evidence. However, most of the remaining markers have not been adequately tested and/or compared against established risk factors for cardiovascular disease. Lastly, although some markers have demonstrated the ability to predict cardiovascular events beyond what current risk factor-based models can offer, their

implementation in clinical practice remains limited, as there is inadequate evidence of their clinical usefulness.

During the search process, a considerable number of studies were found to be ineligible for inclusion in our systematic review. The available studies were primarily cross-sectional in design, and only a limited number of them focused specifically on individuals with T2D and examined the early utility of risk factors and biomarkers in predicting future cardiovascular events. Ultimately, among the 615 studies that underwent full-text review, many were excluded due to study design or outcomes that did not meet our criteria. These findings emphasize the need for better-designed studies in this area to improve our understanding of the prognostic value of markers for cardiovascular disease in individuals with T2D.

It is important to note that most studies included in the final analysis were conducted on people of European, East or South Asian ancestry, with the top-5 countries of recruitment being the United States, UK, China, Japan and Italy. African ancestry and countries were underrepresented. A skewed geographical distribution was also evident regarding countries of author affiliation, with the same top-5 countries dominating the volume of publications. Although the geographical and ancestral imbalance reported here for biomarker studies is less pronounced than what was recently reported for GWAS studies.[450] It highlights the pressing need to enhance data collection and availability in underrepresented populations to promote precision medicine while avoiding exacerbation of existing healthcare disparities.[451]

In our analysis of prognostic markers, we observed that many studies focused on "novel" or "non-traditional" biomarkers. This finding is not surprising considering the significant increase in the number of biomarkers discovered in recent years, and the growing academic interest in exploring their potential for predicting cardiovascular outcomes. In general, the novel biomarker emerging as the best predictor (e.g. NT-proBNP) is consistent with findings in the general population, where it has also been found to be useful as a prognostic marker. [452] Another biomarker that is often evaluated for CVD prediction is high-sensitivity CRP, which has been found in the general population to improve primary CVD risk prediction among asymptomatic middle-aged adults.[452] In our review, however, CRP was found to have low predictive utility

with moderate strength of evidence. This may be related in part to variability in cut-offs used for this marker, the relatively small numbers of studies, or differential effects in diabetes.

While many genetic studies have been conducted to investigate association between polymorphisms and genetic variants with cardiovascular outcomes in diabetes, we found few genetic markers which have been consistently investigated in longitudinal studies, and few which have been consistently replicated to be associated with cardiovascular outcomes. Furthermore, we could only identify one study that utilized a genome-wide association study approach, and identified the rs10911021 variant near *GLUL* to be associated with CV outcome in diabetes, at genome-wide significance. The variant at *GLUL* has subsequently been confirmed in two independent studies, confirming its role as a prognostic marker. [174] Polygenic genetic risk scores also appear to be emerging as a promising approach, and GRS constructed from variants associated with CHD in the general population were found to be helpful for cardiovascular risk stratification in diabetes.[259]

There is a need for a larger number of adequately powered genetic association studies to identify genetic markers associated with cardiovascular disease in diabetes. On the contrary, while dedicated studies among people with T2D were limited, we found several examples of studies that evaluated the utility of applying polygenic risk scores, or genome-wide polygenic risk scores, derived from the general population, in risk stratification of cardiovascular risk among people in T2D. In general, these have fair performance and offered a similar ability to stratify as in patients without diabetes. Given the much larger sample sizes in current published meta-analyses of GWAS for CHD in the general population, this approach will probably be more fruitful in terms of incorporating genetic markers into risk stratification of cardiovascular complications. In the limited studies that have evaluated the added benefit of polygenic risk scores above clinical markers, there is in general a modest, but significant improvement in prediction. Whether polygenic risk scores will become viable options for future risk stratification would partly depend on the availability of these tools, and the cost-effectiveness of adding these measures into clinical practice.

Beyond individual prognostic markers, our review identified several studies that evaluated clinical risk prediction models or cardiovascular risk stratification. While the UKPDS risk engine (developed among subjects with newly diagnosed T2D the UK) and the Framingham risk equation (developed from the general population in the US) were the most widely studied, they do not perform well in contemporary studies of people with T2D. This suggests difficulties in applying certain risk models to current healthcare settings. Nevertheless, our literature review shows that clinical risk models are perhaps the "readiest" for implementation in clinical practice to improve risk stratification in diabetes. On external validation, newer risk scores generally achieved higher discrimination compared to UKPDS and FRS, with Fremantle Diabetes Study 2 (FDS-2) having the highest c-statistic of 0.81 (developed and validated in different populations in Australia). We found that risk models performed better when validated in cohorts that were like the derivation cohort, with c-statistics of 0.699 ± 0.015 and 0.668 ± 0.006 (95% CI) (P=0.018) for concordant and discordant studies, respectively.

In an era when electronic medical record (EMR)-based prediction models are being increasingly used, our results suggest that researchers should focus on the development of population-specific risk models that are intended to be deployed in the same population from which they were developed since the goal should be to achieve the highest predictive accuracy rather than to find a generic model that performs modestly well in all settings. Despite their potential utility and low implementation costs, we found a paucity of evidence showing these risk engines being integrated into clinical practice as calculators. We are aware of several notable exceptions. For example, the Joint Asia Diabetes Evaluation (JADE) program has incorporated several risk prediction algorithms derived from Asian patients with diabetes into a web-based e-health portal, together with a graphical interface and decision support [453], and has been evaluated in different clinical settings, including in randomized clinical trials. [454-457] Many EMR systems offer quick calculations of CVD risk using the American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort Equations based on inputs available in the patient's record, and we recommend that future risk scores found to have high predictive accuracy be made easily accessible to clinicians in their workflow within the EMR.

In this extensive review, we identified a substantial number of studies that had major limitations in their design, as they did not adequately account for established cardiovascular risk factors in their covariate adjustment. Furthermore, among the biomarker studies that considered adjustments for established cardiovascular risk factors, only a minority (6%) evaluated the clinical utility of incorporating the biomarker in risk prediction compared to using clinical risk factors alone. Similar findings were observed in the genetic markers, where only ~4% were tested in multiple studies and incorporating information about improvement in risk prediction.

Given the limitations and gaps that emerged from this review, we recommend that future studies follow several guidelines to improve the quality and impact of studies on precision prognostics in diabetes. First, studies attempting to identify a risk marker should be conducted in prospective or longitudinal cohorts or trials, to provide more robust and reliable data. Second, studies should have sufficient sample size and duration of follow-up (at least 3 years for primary CVD events and at least 1 year for secondary CVD events) to ensure adequate statistical power. Third, studies must adjust for a minimal set of established clinical cardiovascular risk factors, to ensure that any observed associations are not confounded by known risk factors. Finally, studies should attempt to explore the added utility of biomarkers by comparing against prediction using risk models based on established risk factors or available risk engines for cardiovascular events. This would include evaluation of the change in c-statistics after adding risk markers/biomarkers of interest but also consider including additional metrics such as NRI and IDI. We believe that if journals make these requirements mandatory when evaluating such studies, it will help ensure that future studies are best suited for informing future advances in this area. As in any other research field, harmonization of protocols, methods, and analysis pipelines should be encouraged to allow comparisons across studies.

There are several unique strengths of this work. To our knowledge, this represents one of the most comprehensive overviews of the current status of knowledge with regard to risk stratification of cardiovascular outcomes in T2D. We included studies from 1990 onwards, to capture some of the older studies, as well as more contemporary studies. Our inclusion of a broad range of “biomarkers” in the broadest term, including clinical risk factors, novel biomarkers, imaging modalities, genetic polymorphisms, polygenic risk scores, risk prediction models etc.,

allow us to provide an objective overview of the different approaches currently being explored for better risk stratification. In focusing on studies that utilized longitudinal cohorts, we placed the emphasis on studies that would inform prognostication. We focused on “hard” cardiovascular endpoints, rather than also including surrogate endpoints such as carotid intima-medial thickness, to focus on endpoints that would be of greatest clinical relevance.

There are several notable limitations of our study. This includes having to exclude large numbers of cross-sectional studies, given the scale of the systematic review, and the need to focus on longitudinal studies which can best inform clinical practice. We also excluded studies which utilized surrogate markers of cardiovascular events, such as carotid IMT, unless those surrogate endpoints are being investigated as the exposure for predicting “hard” cardiovascular events. We limited our search to articles published in English. Another limitation is that our search terms are perhaps more sensitive for the detection of studies of clinical risk factors and biomarkers compared to genetic factors, and this led to fewer genetic studies being identified as expected. Despite this limitation, we were able to supplement this by adding back some missing articles based on the literature identified and the expertise of the investigators.

In conclusion, our systematic review on prognostic markers for cardiovascular endpoints in T2D identified several novel findings and some important knowledge gaps. We found that NT-proBNP, TnT, TyG, and GRS-CHD had high predictive utility beyond traditional CVD risk factors, with the highest strength of evidence for NT-proBNP. Among genetic markers, there was only sufficient evidence for the polygenic risk score for CHD, and among risk scores, predictive utility was modest on external validation. Given the relatively low number of studies analyzing these novel prognostic factors using rigorous approach, these findings support the need for future studies testing these markers with convincing demonstration of incremental predictive utility. NT-proBNP appears to be the only biomarker ready to be tested prospectively to evaluate its utility in modifying clinical practice for prediction of CVD risk.

Acknowledgements

A.A., M.D-P., H.F., M.F.G. acknowledge support from the Swedish Heart-Lung Foundation (20190470), Swedish Research Council (EXODIAB, 2009-1039; 2018-02837), Swedish Foundation for Strategic Research (LUDC-IRC, 15-0067), EU H2020-JTI-lMl2-2015-05 (Grant agreement number 115974 - BEAt-DKD) to M.F.G. L-L.L. acknowledge UK Medical Research Council Population and Systems Medicine Board (IF048-2022). M.L.K. is supported by Italian Ministry of Health Grant "Ricerca Finalizzata 2019" - GR-2019-12369702. C.H.T.T., C.H, and R.C.W.M. acknowledge support from the Research Grants Council of the Hong Kong Special Administrative Region (CU R4012-18), the Croucher Foundation Senior Medical Research Fellowship, University Grants Committee Research Grants Matching Scheme and Research Committee Postdoctoral Fellowship Scheme of the Chinese University of Hong Kong. F.F.C. acknolwedge the Second Affiliated Hospital of Chongqing Medical University (No. 2022cffkyqdj). T.C. is an international training fellow supported by the Wellcome Trust grant (214205/Z/18/Z). R.W.K. was funded by a Novo Nordisk Foundation (NNF18OC0031650) postdoctoral fellowship. G.Y. and R.C.W.M. acknowledges support from the Provost's Scheme for PhD scholarship from the Chinese University of Hong Kong. Y.Z. acknowledges a Postgraduate Studentship and Vice-Chancellor's PhD scholarship from the Chinese University of Hong Kong. The authors wish to acknowledge the support of librarians from Lund University, Maria Björklund and Krister Aronsson for their expert support with the literature search. N.M. is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125780, R01DK134955).

Contributions of authors

Drs. Gomez, Ma, and Mathioudakis had full access to all the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: R.C.W.M, N.M, M.F.G, A.A.M, A.A, L-L.L, R.W.K, S.C.T, C.H.T, M.D-P, F.C, S.S

Acquisition, analysis, or interpretation of data: R.C.W.M, N.M, A.A, M.F.G, M.D-P, C.H.T, R.W.K, F.C, S.C.T, L-L.L, S.S, A.A.M, T.C, M.P, M.L.M, H.F, S.K, G.Y, Y.Z.

Drafting of the manuscript: R.C.A.M, N.M, M.F.G, A.A, M.L.M, L-L.L, C.H.T, H.F, S.K
Critical revision of the manuscript for important intellectual content: RC.A.M, N.M, M.F.G, A.A, L-L.L, M.L.M, C.H.T, F.C, T.C, M.D-P, H.F, C.H, S.K, S.S, R.W.K, A.A.M, S.C.T, G.Y, Y.Z, M.P, D.S, R.S, D.K.T
Statistical analysis: C.H.T, M.L.M, N.M
A.A, L-L.L, M.L.M, C.H.T contributed equally to this work and are considered co-first authors. M.F.G, R.C.W.M, and N.M supervised all aspects of this work and are considered co-senior authors.

Competing interests

L-L.L. has served as an advisory committee member for Bayer, Boehringer Ingelheim, Novo Nordisk, Procter & Gamble Health, and Viatris; and as a speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novo Nordisk, Roche, Sanofi, Servier, and Zuellig Pharma Therapeutics. She has also received research grants from Abbott, AstraZeneca, and Boehringer Ingelheim. M.L.M. received lecture fees, consultancy, or advisory board fees from Amarin, Amgen, Eli Lilly, Merck Sharp & Dohme, Mylan, Novo Nordisk, Servier, and SlaPharma, all not directly related to this manuscript. R.W.K. has received consulting fees from Novo Nordisk. M.F.G. has received financial and non-financial (in kind) support from Boehringer Ingelheim Pharma GmbH, JDRF International, Eli Lilly, AbbVie, Sanofi-Aventis, Astellas, Novo Nordisk A/S, Bayer AG within EU grant H2020-JTI-lMl2-2015-05 (Grant agreement number 115974 - BEAt-DKD). She has also received financial and in-kind support from Novo Nordisk, Pfizer, Follicum, Coegin Pharma, Abcentra, Probi, Johnson & Johnson within a project funded by the Swedish Foundation for Strategic Research on precision medicine in diabetes (LUDC-IRC #15-0067). Dr. Gomez has received personal consultancy fees from Lilly and Tribune Therapeutics AB. R.C.W.M. has received research grants from AstraZeneca, Bayer, Novo Nordisk, Pfizer, Roche Diagnostics (HK) Ltd, Tricida Inc, and consultancy/speaker honorarium from AstraZeneca, Boehringer Ingelheim, Bayer, Merck. All proceeds have been donated to the Chinese University of Hong Kong to support diabetes research. R.C.W.M. is a co-founder of GemVCare, a technology start-up initiated with support from the Hong Kong Government Innovation and Technology Commission and its Technology Start-up Support Scheme for Universities (TSSSU).

Figures

Figure 1. PRISMA flow diagram detailing the process that led to final study inclusion for review.



Figure 2. Selection of studies to be included for evaluating the associations of biomarkers, genetic markers and non-genetic risk scores with cardiovascular outcomes



Figure 3. A. Top 20 countries of origin and ancestry of the study populations in the included studies. B. Top 20 countries of affiliation and gender distribution of authors for biomarker (BM), genetics (GN) and risk score studies. The data used for this visualization was obtained from PubMed and PubMed Central through manual curation and by applying text mining functions developed using R software version 4.1.2. The final proportions of ancestries were calculated for each unique study and then aggregated as described in detail here: [450]




B.
15%
10%
5%
Gender
70%
Male
30%
Female
Top-20 Countries of Affiliation
17.42%
10.06%
7.85%
7.53%
7.32%
5.19%
5.18%
4.49%
3.68%
3.55%
3.40%
2.77%
2.32%
2.29%
2.23%
2.23%
1.83%
1.34%
1.31%
1.09%
28%
72%
55%
45%
30%
70%
BM
GN
RS

Figure 4. Funneling of non-genetic biomarker studies (A) and genetic biomarkers (B)

A.



B.



Figure 5. Forest plots for three biomarkers (A. NT-proBNP, B. TnT and C. CCTA) with the most evidence for prediction of CVD outcomes. HR, hazard ratio; CI, confidence interval; DM pop N, sample size for diabetes population; Event N, number of individuals developed CVD outcomes; 3p MACE, 3-point major adverse cardiovascular events; HF, heart failure; CHD, coronary heart disease; CVM, cardiovascular mortality; PAD, peripheral artery disease; ACM, all-cause mortality

A.



B.

Troponin T (TnT)

First author	Year	Study population	DM pop N	Event N	Outcome	No. of covariates	Risk of bias	Per unit increase / Cutoff for biomarker	Hazard ratio [95% CI]
McMurray	2011	Mixed	4038	1010	3p MACE, HF	29	Low	>0.028 ng/mL vs. ≤0.028 ng/mL	1.50 [1.06, 2.13]
Keller	2018	Mixed	1034	377	3p MACE	17	Med.	Q4 (>90 ng/L) vs Q1 (≤35 ng/L)	2.10 [1.49, 2.95]
Resl	2016	Mixed	746	171	CHD, Stroke, HF, PAD, ACM	10	Low	per 1 logarithm (ng/L)	1.43 [1.13, 1.81]
Scirica	2016	Mixed	12310	NR	3p MACE, HF	13	Low	per 1 SD of the logarithms (pg/mL)	1.41 [1.32, 1.51]
Everett	2015	Secondary	1984	198	3p MACE, ACM	18	High	≥14 ng/L vs. <14 ng/L	1.56 [1.22, 1.99]
Lepojarvi	2016	Secondary	1053	37	CHD, CVM, HF	11	Low	>14 ng/L vs. ≤14 ng/L	15.50 [5.12, 46.90]
Rørth	2019	Secondary	759	NR	CHD, CVM, HF, ACM	13	Low	per 1 logarithm (ng/L)	1.91 [1.45, 2.51]
Lorenzo-Almoros	2020	Secondary	232	NR	CHD, Stroke	15	Low	per 1 SD (ng/mL)	1.02 [0.84, 1.23]



C.

Coronary computed tomography angiography (CCTA) / angiography

First author	Year	Study population	DM pop N	Event N	Outcome	No. of covariates	Risk of bias	Per unit increase / Cutoff for biomarker	Hazard ratio [95% CI]
Cosson	2011	Primary	688	98	3p MACE, Revasc, HF, PAD	5	High	presence of silent CAD vs. absence	2.10 [1.09, 4.05]
Lee	2017	Primary	933	94	CHD, Revasc, ACM	7	Medium	obstructive CAD ≥50% vs. <50%	3.83 [2.45, 5.98]
Halon	2019	Primary	630	24	CHD	4	Low	mild plaque calcification <50% vs. other plaques	2.60 [1.13, 5.97]
Halon	2016	Primary	630	24	CHD, CVM, Angina	3	High	per 1 quartile of Gensini score	2.50 [1.67, 3.74]
Tian	2019	Mixed	164	20	CHD, CVM, Revasc, Angina	9	Medium	obstructive CAD vs. no CAD	7.79 [1.75, 34.70]



Figure 6. Meta-analysis of A. NT-proBNP and B. TnT for predicting cardiovascular outcomes. Note: P_Q is the *p*-value obtained from the Cochran's Q test. HR, hazard ratio; CI, confidence interval; DM pop N, sample size for diabetes population; Event N, number of individuals developed CVD outcomes

A.



B.



Figure 7. Forest plots of genetic markers for predicting cardiovascular outcomes (A. genetic risk scores, B. *GLUL* variant rs10911021. HR, hazard ratio; CI, confidence interval; DM pop N, sample size for diabetes population; Event N, number of individuals developed CVD outcomes; 3p MACE, 3-point major adverse cardiovascular events

A.

Genetic risk scores (GRS) derived from coronary artery disease loci known from general population

First author	Year	Study population	Population ancestry	No. of variants	DM pop N	Event N	Outcome	No. of covariates	Risk of bias	Per unit increase	HR / OR [95% CI]
Cox	2014	Primary	European American	30	983	101	CVM	7	High	per 1 SD	1.46 [1.08, 1.97]
Qi	2011	Mixed	non-Hispanic Whites	5	2506	1076	CHD	7	High	per 1 GRS unit	1.19 [1.13, 1.26] †
Mccaffery	2015	Mixed	Multi-ethnic	153	4016	NR	3p MACE, Angina	7	High	per 1 SD	1.17 [1.08, 1.26]
Morieri	2018	Mixed	Non-Hispanic Whites	204	5104	675	CHD	9	Medium	per 1 SD	1.17 [1.08, 1.27]
Morieri	2018	Mixed	Non-Hispanic Whites	204	1931	163	CHD	9	Medium	per 1 SD	1.32 [1.13, 1.55]
Morieri	2018	Mixed	African-Americans	204	1398	122	CHD	9	Medium	per 1 SD	0.95 [0.79, 1.14]
Morieri	2018	Mixed	Hispanics	204	529	61	CHD	9	Medium	per 1 SD	1.20 [0.92, 1.57]
Morieri	2018	Mixed	Asians	204	469	25	CHD	9	Medium	per 1 SD	1.98 [1.31, 2.99]



† odd ratio (OR) with 95% confident interval (CI) was reported

B.

rs10911021 at *GLUL*

First author	Year	Study population	Population ancestry	DM pop N	Event N	Outcome	No. of covariates	Risk of bias	Comparison group vs. reference group	HR / OR [95% CI]
Qi	2013	Primary	White (females)	1326	350	CHD	2	Low	C allele vs. T allele	1.34 [1.10, 1.63] †
Qi	2013	Primary	White (males)	984	319	CHD	2	Low	C allele vs. T allele	1.49 [1.20, 1.86] †
Baeney	2016	Primary	White/European	1537	160	CHD	1	Medium	C allele vs. T allele	1.25 [0.94, 1.67] †
Huggins	2016	Primary	Multi-ethnic	3295	NR	3p MACE, Angina	5	Medium	C allele vs. T allele	1.17 [1.01, 1.36]



† odd ratio (OR) with 95% confident interval (CI) was reported

Figure 8. Meta-analysis of C-statistics of risk scores for predicting cardiovascular outcomes. Internal validation results are shown in Figure 8A and external validation results in Figure 8B. CI, confidence interval.

A.



B.

Meta-analysis for the c-statistics of risk scores (external validation cohorts)

First author	Year	Risk score	Year original risk score published	Derivation country(ies)	Validation cohort	Country(ies) of validation cohort	Risk of bias	Weight (%)	C-statistic [95% CI]
Basu	2017	ACC/AHA PCEs	2013	United States	LOOK AHEAD	United States	High	2.87%	0.66 [0.64, 0.68]
Kengne	2011	ADVANCE	2011	Europe/Asia	DIABHYCAR	Multinational	High	2.26%	0.68 [0.65, 0.72]
vanderLeeuw	2015	ADVANCE	2011	Europe/Asia	EPIC-NL	Netherlands	Medium	1.04%	0.62 [0.54, 0.70]
vanderLeeuw	2015	ADVANCE	2011	Europe/Asia	EPIC-Potsdam	Germany	Medium	1.04%	0.67 [0.59, 0.75]
vanderLeeuw	2015	ADVANCE	2011	Europe/Asia	SMART	Netherlands	Medium	0.80%	0.68 [0.59, 0.77]
Wan	2018	ADVANCE	2011	Europe/Asia	Hong Kong Hospital Authority (men)	China	Medium	3.37%	0.69 [0.68, 0.70]
Wan	2018	ADVANCE	2011	Europe/Asia	Hong Kong Hospital Authority (women)	China	Medium	3.37%	0.71 [0.70, 0.72]
Read	2018	ADVANCE	2011	Europe/Asia	National Scottish Diabetes Register	Scotland	Medium	3.52%	0.67 [0.66, 0.67]
Yu	2018	Cambridgeshire	2018	United Kingdom	RCT of Peer Support in Type 2 Diabetes trial	United Kingdom	Medium	3.51%	0.71 [0.70, 0.72]
vanderLeeuw	2015	CHS	2013	United States	EPIC-NL	Netherlands	Medium	0.95%	0.54 [0.46, 0.62]
vanderLeeuw	2015	CHS	2013	United States	EPIC-Potsdam	Germany	Medium	0.87%	0.61 [0.52, 0.70]
vanderLeeuw	2015	CHS	2013	United States	SMART	Netherlands	Medium	0.80%	0.68 [0.59, 0.77]
vanderLeeuw	2015	CHS	2013	United States	National Scottish Diabetes Register	Scotland	Medium	3.52%	0.67 [0.67, 0.68]
Lagani	2015	CVD-DCCT	2015	United States	Chorleywood Medical Center	United Kingdom	High	0.86%	0.71 [0.62, 0.81]
Lagani	2015	CVD-EDIC	2015	United States	Chorleywood Medical Center	United Kingdom	High	0.38%	0.66 [0.51, 0.81]
vanderLeeuw	2015	CVD-EDIC	2015	United States	EPIC-NL	Netherlands	Medium	1.04%	0.58 [0.50, 0.66]
vanderLeeuw	2015	CVD-EDIC	2015	United States	EPIC-Potsdam	Germany	Medium	1.04%	0.68 [0.60, 0.76]
vanderLeeuw	2015	CVD-EDIC	2015	United States	SMART	Netherlands	Medium	0.74%	0.69 [0.59, 0.79]
Read	2018	CVD-EDIC	2015	United States	National Scottish Diabetes Register	Scotland	Medium	3.53%	0.67 [0.67, 0.67]
Davis	2020	FDS-2	2020	Australia	Busselton Health Study	Australia	High	1.14%	0.81 [0.74, 0.88]
vanderHeijden	2009	FRS	1998	United States	Hoorn Study	Netherlands	Medium	0.48%	0.63 [0.50, 0.76]
Piniés	2014	FRS-RS	2014	Spain	BASCORE	Spain	Medium	1.24%	0.58 [0.51, 0.65]
Quan	2019	JADE	2009	Asia/Pacific	Hong Kong Dataset	China	High	3.55%	0.68 [0.68, 0.69]
vanderLeeuw	2015	NDR	2008	Sweden	EPIC-NL	Netherlands	Medium	1.04%	0.64 [0.56, 0.72]
vanderLeeuw	2015	NDR	2008	Sweden	EPIC-Potsdam	Germany	Medium	1.14%	0.67 [0.60, 0.74]
vanderLeeuw	2015	NDR	2008	Sweden	SMART	Netherlands	Medium	0.74%	0.64 [0.54, 0.74]
Wan	2018	NDR	2008	Sweden	Hong Kong Hospital Authority (men)	China	Medium	3.39%	0.69 [0.68, 0.70]
Wan	2018	NDR	2008	Sweden	Hong Kong Hospital Authority (women)	China	Medium	3.37%	0.71 [0.70, 0.72]
Read	2018	NDR	2008	Sweden	National Scottish Diabetes Register	Scotland	Medium	3.52%	0.66 [0.66, 0.67]
Elley	2010	NZ DCS	2010	New Zealand	New Zealand (South)	New Zealand	High	3.28%	0.67 [0.66, 0.68]
vanderLeeuw	2015	NZ DCS	2010	New Zealand	EPIC-NL	Netherlands	Medium	1.04%	0.63 [0.55, 0.71]
vanderLeeuw	2015	NZ DCS	2010	New Zealand	EPIC-Potsdam	Germany	Medium	1.14%	0.66 [0.59, 0.73]
vanderLeeuw	2015	NZ DCS	2010	New Zealand	SMART	Netherlands	Medium	0.74%	0.67 [0.57, 0.77]
Wan	2018	NZ DCS	2010	New Zealand	Hong Kong Hospital Authority (men)	China	Medium	3.39%	0.69 [0.68, 0.70]
Wan	2018	NZ DCS	2010	New Zealand	Hong Kong Hospital Authority (women)	China	Medium	3.37%	0.71 [0.70, 0.72]
Read	2018	QRISK2	2008	England/Wales	National Scottish Diabetes Register	Scotland	Medium	3.52%	0.68 [0.67, 0.68]
Basu	2017	RECODe	2017	United States	LOOK AHEAD	United States	High	3.09%	0.73 [0.71, 0.75]
vanderHeijden	2009	SCORE	2003	Europe	Hoorn Study	Netherlands	Medium	0.51%	0.66 [0.54, 0.78]
Venäläinen	2020	SPRINT	2017	United States	ACCORD	United States	High	2.87%	0.69 [0.67, 0.71]
Simmons	2009	UKPDS	1998	United Kingdom	Epic Norfolk	United Kingdom	Medium	1.37%	0.72 [0.66, 0.78]
Davis	2009	UKPDS	1998	United Kingdom	FDS	Australia	Medium	0.95%	0.68 [0.60, 0.76]
Kengne	2010	UKPDS	1998	United Kingdom	ADVANCE	Europe/Asia	Medium	2.26%	0.68 [0.65, 0.72]
vanDieren	2011	UKPDS	1998	United Kingdom	Epic-NL; Epic-Potsdam	Netherlands/Germany	Medium	0.37%	0.66 [0.51, 0.81]
Tanaka	2013	UKPDS	1998	United Kingdom	JDCS/J-EDIT	Japan	High	1.27%	0.69 [0.63, 0.76]
Piniés	2014	UKPDS	1998	United Kingdom	BASCORE	Spain	Medium	1.66%	0.62 [0.57, 0.67]
Basu	2017	UKPDS	1998	United Kingdom	LOOK AHEAD	United States	High	2.87%	0.67 [0.65, 0.69]
Quan	2019	UKPDS	1998	United Kingdom	Hong Kong Dataset	China	High	3.55%	0.68 [0.67, 0.68]
Quan	2019	UKPDS	1998	United Kingdom	Hong Kong Dataset	China	High	3.54%	0.65 [0.65, 0.66]
Venäläinen	2020	UKPDS	1998	United Kingdom	Hoorn Study	Netherlands	High	0.64%	0.66 [0.55, 0.77]
Yu	2019	Zhengzhou University	2019	China	Zhengzhou University	China	Low	3.44%	0.75 [0.74, 0.76]
							Overall	100%	0.68 [0.67, 0.69]

Random-effects REML model

I^2 = 97.18%; τ^2 = 0.001; P_Q = 1.99e-141; C-statistic [95% CI] = 0.68[0.67 - 0.69], P = 0

Fixed-effects model

I^2 = 94.06% ; P_Q = 1.99e-141; C-statistic [95% CI] = 0.68[0.68 - 0.68], P = 0



Tables.

Table 1. Performance of the prediction of 3 biomarkers with the most evidence. Notes: Data on improvement in C-statistics was collected from the study as reported or derived from a comparison of C-statistics from reference-model with C-statistics from reference-model + novel biomarker. NR: Not Reported

Biomarker	**Study**	**Improvement in C-statistics**		**NRI**		**IDI**	
		Yes/No	**Estimate (95% CI) and p-value**	**NRI (95% CI)**	**p-value**	**IDI (95% CI)**	**p-value**
NT-proBNP	Sharma 2020	Yes	0.050 (CI and p value NR)	0.3854 (0.3037, 0.4721)	**P<0.05**	0.0877 (0.077-0.0976)	**P<0.05**
	Wolsk 2017	Yes	0.01 (CI NR), **P<0.05**	0.106 (5.7–16.6)	**P<0.05**	0.08 (0.03-1.6)	**P<0.05**
	Wong 2019	Yes	0.03 (CI NR), **P=0.001**	0.345 (0.238-0.451)	**P <0.001**	0.012 (0.007-0.017)	**P<0.001**
	Scirica 2016	Yes	0.07 (CI NR), **P<0.001**	0.0379 (0.0321-0.0438)	**P<0.05**	0.48 (0.41-0.55)	**P<0.05**
	Van der Leeuw 2016	Yes (SMART)	0.02 (0.00-0.04), P value NR	0.27 (0.10-0.44)	**P<0.05**		
		Yes (EPIC-NL)	0.02 (0.00–0.05), P value NR	0.50 (0.26-0.73)	**P<0.05**		
TnT	Lepojarvi 2016	Yes	0.101, (CI and P value NR),	0.231 (0.067-0.394)	**p <0.01**	0.054 (0.031-0.077)	**p <0.001**
	Scirica 2016	Yes	0.07 (CI NR), **P<0.001**	0.44 (0.38-0.51)	**P<0.05**	0.0285 (0.0233-0.0336)	**P<0.05**
	Rørth 2019	**Yes**	0.018 (CI NR), **P=0.02**	0.150 (0.051-0.261)	**P=0.007**	0.032 (0.012-0.064)	**P<0.001**
CCTA	Lee 2017	Yes	0.072 (CI NR), **P= 0.0349**	0.55 (0.343-0.757)	**P<0.0001**	0.046 (0.02-0.072)	**P= 0.0006**
	Halon 2016	Yes	0.35 (CI NR), **P= 0.021**	0.632	NR	0.647	NR
	Cosson 2011	Yes	0.083 (CI NR), **P <0.0001**				

Table 2. Conclusion and strength of the evidence

	A	B	C	D	E	F	G	H
Prognostic Biomarker	**No. of studies with all 3 performance indicators satisfied**	**No. of pooled meta-analyses showing significant association**	**No. of pooled meta-analyses showing significant association (excluding high risk of bias)**	**Non-pooled analyses showed that >=75% of studies had significant association**	**Persistent association on sensitivity analysis for non-pooled analyses (excluding high risk of bias)**	**Consistency in definition of prognostic biomarker used in analysis**	**Conclusion (predictive utility)**	**Strength of Evidence**
NT-proBNP	3	2/2	2/2	Yes	Yes	Yes	High	High
CRP	0	1/2	1/2	No	No	No	Low	Moderate
TnT	4	2/3	1/3	Yes	Yes	No	High	Moderate
CACS	0	0	0	Yes	No	No	Low	Low
CCTA	2	0	0	Yes	No	No	Moderate	Low
SPECT	1	0	0	Yes	No	No	Moderate	Low
PWV	0	1/1	1/1	Yes	Yes	No	Moderate	Moderate
Gal-3	0	0	0	Yes	Yes	No	Low	Low
TnI	1	0	0	No	No	No	Low	Low
Carotid plaque	0	0	0	Yes	Yes	No	Low	Low
GDF-15	0	0	0	No	No	No	Low	Low
TyG	1	1/1	NA	Yes	No	Yes	High	Moderate
GRS-CHD	1	1/1	1/1	Yes	No	No	High	Moderate

Table includes genetic and non-genetic biomarkers showing improvement in prediction performance (i.e. at least one of c-statistic, NRI, IDI) and in more than 1 study (corresponding to all markers in green boxes in Figures 4A and Figures 4B). Notes: Predictive utility was classified as high (3 point) moderate (2 points) or low (<2 points) based on the criteria defined in columns A, B and D (Column A: >0 =1 point; Column B: >0 =1 point, Column D: "Yes" = 1 point). Strength of Evidence was classified as High (4 points), moderate (2 or 3 points) and low (< 2 points) based on criteria defined in columns B, C , E and F (Column B: at least one meta-analysis conducted [regardless of outcome] = 1 point; Column C: exclusion of high risk of bias studies did not alter inferences from meta-analyses [same number as in column B] = 1 point; Column E: exclusion of high risk of bias studies did not alter inferences from non-pooled analyses [YES] = 1 point; Column F: "yes" = 1 point).

References

1 Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K. & Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* **339**, 229-234, doi:10.1056/nejm199807233390404 (1998).

2 Nathan, D. M. *et al.* Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. *N Engl J Med* **387**, 1063-1074, doi:10.1056/NEJMoa2200433 (2022).

3 IDF Diabetes Atlas. *Diabetes around the world in 2021*, <https://diabetesatlas.org/> (2021).

4 van Dieren, S. *et al.* External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. *Diabetologia* **54**, 264-270, doi:10.1007/s00125-010-1960-0 (2011).

5 Szymonifka, J. *et al.* Cardiovascular disease risk prediction for people with type 2 diabetes in a population-based cohort and in electronic health record data. *JAMIA Open* **3**, 583-592, doi:10.1093/jamiaopen/ooaa059 (2020).

6 Ho, J. C. *et al.* Evaluation of available risk scores to predict multiple cardiovascular complications for patients with type 2 diabetes mellitus using electronic health records. *Computer Methods and Programs in Biomedicine Update* **3**, 100087, doi:https://doi.org/10.1016/j.cmpbup.2022.100087 (2023).

7 Chung, W. K. *et al.* Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* **43**, 1617-1635, doi:10.2337/dci20-0022 (2020).

8 Nolan, J. J. *et al.* ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes. *Diabetes Care* **45**, 261-266, doi:10.2337/dc21-2216 (2022).

9 Tobias, e. a. Precision Medicine in Diabetes: Second international consensus report. *Nat Med* **Under review** (2023).

10 Association, A. D. Economic Costs of Diabetes in the U.S. in 2017. *Diabetes Care* **41**, 917-928, doi:10.2337/dci18-0007 (2018).

11 Centers for Disease Control and Prevention. *Coexisting Conditions and Complications*, <https://www.cdc.gov/diabetes/data/statistics-report/coexisting-conditions-complications.html> (2018).

12 Damen, J. A. *et al.* Prediction models for cardiovascular disease risk in the general population: systematic review. *BMJ* **353**, i2416, doi:10.1136/bmj.i2416 (2016).

13 Zhiting, G. *et al.* Cardiovascular disease risk prediction models in the Chinese population- a systematic review and meta-analysis. *BMC Public Health* **22**, 1608, doi:10.1186/s12889-022-13995-z (2022).

14 Damen, J. A. *et al.* Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. *BMC Med* **17**, 109, doi:10.1186/s12916-019-1340-7 (2019).

15 Lin, J. S. *et al.* (2018).

16 Romero-Cabrera, J. L., Ankeny, J., Fernández-Montero, A., Kales, S. N. & Smith, D. L. A Systematic Review and Meta-Analysis of Advanced Biomarkers for Predicting

Incident Cardiovascular Disease among Asymptomatic Middle-Aged Adults. *Int J Mol Sci* **23**, doi:10.3390/ijms232113540 (2022).
17 van Holten, T. C. *et al.* Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. *PLoS One* **8**, e62080, doi:10.1371/journal.pone.0062080 (2013).
18 Guasti, L. *et al.* TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis. *Intern Emerg Med* **16**, 201-207, doi:10.1007/s11739-020-02470-5 (2021).
19 Rienks, J., Barbaresko, J. & Nöthlings, U. Association of Polyphenol Biomarkers with Cardiovascular Disease and Mortality Risk: A Systematic Review and Meta-Analysis of Observational Studies. *Nutrients* **9**, doi:10.3390/nu9040415 (2017).
20 Gohel, V., Jones, J. A. & Wehler, C. J. Salivary biomarkers and cardiovascular disease: a systematic review. *Clin Chem Lab Med* **56**, 1432-1442, doi:10.1515/cclm-2017-1018 (2018).
21 Kanbay, M. *et al.* Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. *Int Urol Nephrol* **48**, 2029-2042, doi:10.1007/s11255-016-1387-8 (2016).
22 Heianza, Y., Ma, W., Manson, J. E., Rexrode, K. M. & Qi, L. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies. *J Am Heart Assoc* **6**, doi:10.1161/JAHA.116.004947 (2017).
23 Wallace, T. C., Slavin, M. & Frankenfeld, C. L. Systematic Review of Anthocyanins and Markers of Cardiovascular Disease. *Nutrients* **8**, doi:10.3390/nu8010032 (2016).
24 Emadian, A., Andrews, R. C., England, C. Y., Wallace, V. & Thompson, J. L. The effect of macronutrients on glycaemic control: a systematic review of dietary randomised controlled trials in overweight and obese adults with type 2 diabetes in which there was no difference in weight loss between treatment groups. *Br J Nutr* **114**, 1656-1666, doi:10.1017/S0007114515003475 (2015).
25 Yun, H., Noh, N. I. & Lee, E. Y. Genetic risk scores used in cardiovascular disease prediction models: a systematic review. *Rev Cardiovasc Med* **23**, 8, doi:10.31083/j.rcm2301008 (2022).
26 Jeong, E. G. *et al.* Depth and combined infection is important predictor of lower extremity amputations in hospitalized diabetic foot ulcer patients. *Korean J Intern Med* **33**, 952-960, doi:10.3904/kjim.2016.165 (2018).
27 Page, M. J. *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* **372**, n71, doi:10.1136/bmj.n71 (2021).
28 Visseren, F. L. J. *et al.* 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* **42**, 3227-3337, doi:10.1093/eurheartj/ehab484 (2021).
29 Wells GA, S. B., O'Connell D, Peterson J, Welch V, Losos M, & Tugwell P. *The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses*, <https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp> (
30 Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *Journal of Statistical Software* **36**, 1 - 48, doi:10.18637/jss.v036.i03 (2010).
31 Owens, D. K. *et al.* AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. *J Clin Epidemiol* **63**, 513-523, doi:10.1016/j.jclinepi.2009.03.009 (2010).

41

32 Aromataris E, M. Z. E. *JBI Manual for Evidence Synthesis. JBI*, < https://doi.org/10.46658/JBIMES-20-01> (2020).
33 Benjamin, I. J. *et al.* 2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. *Circulation* **143**, e1035-e1087, doi:doi:10.1161/CIR.0000000000000963 (2021).
34 Aboyans, V. *et al.* The prognosis of diabetic patients with high ankle-brachial index depends on the coexistence of occlusive peripheral artery disease. *J Vasc Surg* **53**, 984-991, doi:10.1016/j.jvs.2010.10.054 (2011).
35 Abu-Lebdeh, H. S., Hodge, D. O. & Nguyen, T. T. Predictors of macrovascular disease in patients with type 2 diabetes mellitus. *Mayo Clin Proc* **76**, 707-712, doi:10.4065/76.7.707 (2001).
36 Afarideh, M. *et al.* Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes. *Atherosclerosis* **254**, 42-51, doi:10.1016/j.atherosclerosis.2016.09.009 (2016).
37 Afsharian, S. *et al.* Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes - a 10-year follow-up: Tehran Lipid and Glucose Study. *Diabetes Metab Res Rev* **32**, 596-606, doi:10.1002/dmrr.2776 (2016).
38 Alele, J. D., Luttrell, L. M., Hollis, B. W., Luttrell, D. K. & Hunt, K. J. Relationship between vitamin D status and incidence of vascular events in the Veterans Affairs Diabetes Trial. *Atherosclerosis* **228**, 502-507, doi:10.1016/j.atherosclerosis.2013.03.024 (2013).
39 Alkhalaf, A. *et al.* Sex specific association between carnosinase gene CNDP1 and cardiovascular mortality in patients with type 2 diabetes (ZODIAC-22). *J Nephrol* **28**, 201-207, doi:10.1007/s40620-014-0096-6 (2015).
40 Anand, D. V., Lahiri, A., Lim, E., Hopkins, D. & Corder, R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. *J Am Coll Cardiol* **47**, 1850-1857, doi:10.1016/j.jacc.2005.12.054 (2006).
41 Anand, D. V. *et al.* Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. *Eur Heart J* **27**, 713-721, doi:10.1093/eurheartj/ehi808 (2006).
42 Anavekar, N. S. *et al.* Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. *Kidney Int Suppl*, S50-55, doi:10.1111/j.1523-1755.2004.09213.x (2004).
43 Angiolillo, D. J. *et al.* Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. *J Am Coll Cardiol* **50**, 1541-1547, doi:10.1016/j.jacc.2007.05.049 (2007).
44 Anyanwagu, U., Donnelly, R. & Idris, I. Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort. *Am J Nephrol* **49**, 146-155, doi:10.1159/000496276 (2019).
45 Apperloo, E. M., Pena, M. J., de Zeeuw, D., Denig, P. & Heerspink, H. J. L. Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study. *Diabetes Obes Metab* **20**, 1377-1383, doi:10.1111/dom.13226 (2018).

46 Araki, S. *et al.* Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. *Diabetes Care* **36**, 1248-1253, doi:10.2337/dc12-1298 (2013).
47 Avogaro, A. *et al.* Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. *Diabetes Care* **30**, 1241-1247, doi:10.2337/dc06-2558 (2007).
48 Azab, B., Chainani, V., Shah, N. & McGinn, J. T. Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: a 4-year follow-up study. *Angiology* **64**, 456-465, doi:10.1177/0003319712455216 (2013).
49 Azevedo, M. J. *et al.* Value of diagnostic tools for myocardial ischemia used in routine clinical practice to predict cardiac events in patients with type 2 diabetes mellitus: a prospective study. *Arq Bras Endocrinol Metabol* **50**, 46-52, doi:10.1590/s0004-27302006000100007 (2006).
50 Bacci, S. *et al.* The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. *Diabetes* **60**, 1000-1007, doi:10.2337/db10-1300 (2011).
51 Backhaus, S. J. *et al.* Cardiac Magnetic Resonance Myocardial Feature Tracking for Optimized Risk Assessment After Acute Myocardial Infarction in Patients With Type 2 Diabetes. *Diabetes* **69**, 1540-1548, doi:10.2337/db20-0001 (2020).
52 Basu, S. *et al.* Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S. *Diabetes Care* **41**, 586-595, doi:10.2337/dc17-2002 (2018).
53 Basu, S., Sussman, J. B., Berkowitz, S. A., Hayward, R. A. & Yudkin, J. S. Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. *Lancet Diabetes Endocrinol* **5**, 788-798, doi:10.1016/s2213-8587(17)30221-8 (2017).
54 Bates, R. E. *et al.* Impact of Stress Testing for Coronary Artery Disease Screening in Asymptomatic Patients With Diabetes Mellitus: A Community-Based Study in Olmsted County, Minnesota. *Mayo Clin Proc* **91**, 1535-1544, doi:10.1016/j.mayocp.2016.07.013 (2016).
55 Beaney, K. E. *et al.* Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids. *Cardiovasc Diabetol* **15**, 115, doi:10.1186/s12933-016-0435-0 (2016).
56 Beilin, J., Stanton, K. G., McCann, V. J., Knuiman, M. W. & Divitini, M. L. Microalbuminuria in type 2 diabetes: an independent predictor of cardiovascular mortality. *Aust N Z J Med* **26**, 519-525, doi:10.1111/j.1445-5994.1996.tb00598.x (1996).
57 Bell, K. J. L. *et al.* Prognostic impact of systolic blood pressure variability in people with diabetes. *PLoS One* **13**, e0194084, doi:10.1371/journal.pone.0194084 (2018).
58 Berkelmans, G. F. N. *et al.* Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. *Eur Heart J* **40**, 2899-2906, doi:10.1093/eurheartj/ehy839 (2019).

59 Bernard, S. *et al.* Relation between XbA1 apolipoprotein B gene polymorphism and cardiovascular risk in a type 2 diabetic cohort. *Atherosclerosis* **175**, 177-181, doi:10.1016/j.atherosclerosis.2004.03.017 (2004).
60 Bernard, S. *et al.* Incremental predictive value of carotid ultrasonography in the assessment of coronary risk in a cohort of asymptomatic type 2 diabetic subjects. *Diabetes Care* **28**, 1158-1162, doi:10.2337/diacare.28.5.1158 (2005).
61 Bianco, H. T. *et al.* Relevance of target-organ lesions as predictors of mortality in patients with diabetes mellitus. *Arq Bras Cardiol* **103**, 272-281, doi:10.5935/abc.20140112 (2014).
62 Biscetti, F. *et al.* Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: a prospective cohort study. *Cardiovasc Diabetol* **19**, 170, doi:10.1186/s12933-020-01151-z (2020).
63 Bonito, B., Silva, A. P., Rato, F., Santos, N. & Neves, P. L. Resistin as a predictor of cardiovascular hospital admissions and renal deterioration in diabetic patients with chronic kidney disease. *J Diabetes Complications* **33**, 107422, doi:10.1016/j.jdiacomp.2019.107422 (2019).
64 Bosevski, M., Borozanov, V., Tosev, S. & Georgievska-Ismail, L. Is assessment of peripheral endothelial dysfunction useful tool for risk stratification of type 2 diabetic patients with manifested coronary artery disease? *Int J Cardiol* **131**, 290-292, doi:10.1016/j.ijcard.2007.08.011 (2009).
65 Bouchi, R. *et al.* Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes. *Journal of Diabetes Investigation* **3**, 148-155, doi:10.1111/j.2040-1124.2011.00155.x (2012).
66 Brownrigg, J. R. *et al.* Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. *Lancet Diabetes Endocrinol* **4**, 588-597, doi:10.1016/s2213-8587(16)30057-2 (2016).
67 Bruce, D. G., Davis, W. A., Starkstein, S. E. & Davis, T. M. A prospective study of depression and mortality in patients with type 2 diabetes: the Fremantle Diabetes Study. *Diabetologia* **48**, 2532-2539, doi:10.1007/s00125-005-0024-3 (2005).
68 Bruno, G., Barutta, F., Landi, A., Cavallo Perin, P. & Gruden, G. NT-proBNP linking low-moderately impaired renal function and cardiovascular mortality in diabetic patients: the population-based Casale Monferrato Study. *PLoS One* **9**, e114855, doi:10.1371/journal.pone.0114855 (2014).
69 Bruno, G. *et al.* N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. *Diabetes Care* **36**, 2677-2682, doi:10.2337/dc13-0353 (2013).
70 Bruno, G. *et al.* Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. *Diabetologia* **48**, 427-434, doi:10.1007/s00125-004-1667-1 (2005).
71 Bruno, G. *et al.* Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. *Diabetes Care* **27**, 2689-2694, doi:10.2337/diacare.27.11.2689 (2004).
72 Burgess, D. C. *et al.* Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and

Event Lowering in Diabetes (FIELD) study. *Eur Heart J* **31**, 92-99, doi:10.1093/eurheartj/ehp377 (2010).
73 Busch, M. *et al.* The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. *Am J Kidney Dis* **48**, 571-579, doi:10.1053/j.ajkd.2006.07.009 (2006).
74 Böger, C. A. *et al.* RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. *Atherosclerosis* **183**, 121-129, doi:10.1016/j.atherosclerosis.2005.03.006 (2005).
75 Cardona, A. *et al.* Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis. *BMJ Open Diabetes Res Care* **7**, e000718, doi:10.1136/bmjdrc-2019-000718 (2019).
76 Cardoso, C. R., Ferreira, M. T., Leite, N. C. & Salles, G. F. Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio deJaneiro Type 2 Diabetes Cohort Study. *Diabetes Care* **36**, 3772-3778, doi:10.2337/dc13-0506 (2013).
77 Cardoso, C. R., Leite, N. C. & Salles, G. F. Prognostic Importance of C-Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study. *J Am Heart Assoc* **5**, doi:10.1161/jaha.116.004554 (2016).
78 Cardoso, C. R., Salles, G. F. & Deccache, W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. *J Diabetes Complications* **17**, 169-178, doi:10.1016/s1056-8727(02)00206-4 (2003).
79 Cardoso, C. R. L., Leite, N. C., Moram, C. B. M. & Salles, G. F. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. *Cardiovasc Diabetol* **17**, 33, doi:10.1186/s12933-018-0677-0 (2018).
80 Cardoso, C. R. L., Leite, N. C. & Salles, G. F. Prognostic importance of visit-to-visit blood pressure variability for micro- and macrovascular outcomes in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study. *Cardiovasc Diabetol* **19**, 50, doi:10.1186/s12933-020-01030-7 (2020).
81 Cardoso, C. R. L., Salles, G. C., Leite, N. C. & Salles, G. F. Prognostic impact of carotid intima-media thickness and carotid plaques on the development of micro- and macrovascular complications in individuals with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. *Cardiovasc Diabetol* **18**, 2, doi:10.1186/s12933-019-0809-1 (2019).
82 Carlsson, A. C. *et al.* Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach. *Ups J Med Sci* **125**, 37-43, doi:10.1080/03009734.2019.1696430 (2020).
83 Carlsson, A. C. *et al.* Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes. *Cardiovasc Diabetol* **15**, 40, doi:10.1186/s12933-016-0359-8 (2016).
84 Carnethon, M. R. *et al.* Association of weight status with mortality in adults with incident diabetes. *Jama* **308**, 581-590, doi:10.1001/jama.2012.9282 (2012).

85 Casiglia, E. *et al.* Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. *Eur J Epidemiol* **16**, 677-684, doi:10.1023/a:1007673123716 (2000).
86 Cavalot, F. *et al.* Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. *Diabetes Care* **34**, 2237-2243, doi:10.2337/dc10-2414 (2011).
87 Cavalot, F. *et al.* Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. *J Clin Endocrinol Metab* **91**, 813-819, doi:10.1210/jc.2005-1005 (2006).
88 Cea Soriano, L., Johansson, S., Stefansson, B. & Rodríguez, L. A. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. *Cardiovasc Diabetol* **14**, 38, doi:10.1186/s12933-015-0204-5 (2015).
89 Cederholm, J. *et al.* Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. *Diabetes Care* **31**, 2038-2043, doi:10.2337/dc08-0662 (2008).
90 Celis-Morales, C. A. *et al.* Associations Between Diabetes and Both Cardiovascular Disease and All-Cause Mortality Are Modified by Grip Strength: Evidence From UK Biobank, a Prospective Population-Based Cohort Study. *Diabetes Care* **40**, 1710-1718, doi:10.2337/dc17-0921 (2017).
91 Ceriello, A. *et al.* Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. *Cardiovasc Diabetol* **19**, 176, doi:10.1186/s12933-020-01147-9 (2020).
92 Cha, S. A. *et al.* Time- and frequency-domain measures of heart rate variability predict cardiovascular outcome in patients with type 2 diabetes. *Diabetes Res Clin Pract* **143**, 159-169, doi:10.1016/j.diabres.2018.07.001 (2018).
93 Cha, S. A. *et al.* Diabetic Cardiovascular Autonomic Neuropathy Predicts Recurrent Cardiovascular Diseases in Patients with Type 2 Diabetes. *PLoS One* **11**, e0164807, doi:10.1371/journal.pone.0164807 (2016).
94 Chacko, K. M. *et al.* Heart rate recovery predicts mortality and cardiovascular events in patients with type 2 diabetes. *Med Sci Sports Exerc* **40**, 288-295, doi:10.1249/mss.0b013e31815c4844 (2008).
95 Chan, J. C. *et al.* Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis. *Am J Med* **127**, 616-624, doi:10.1016/j.amjmed.2014.03.018 (2014).
96 Chang, C. W. *et al.* The First Harmonic of Radial Pulse as an Early Predictor of Silent Coronary Artery Disease and Adverse Cardiac Events in Type 2 Diabetic Patients. *Cardiology Research and Practice* **2018**, doi:10.1155/2018/5128626 (2018).
97 Chang, L. H. *et al.* The Ankle Brachial Index Exhibits Better Association of Cardiovascular Prognosis Than Non-High-Density Lipoprotein Cholesterol in Type 2 Diabetes. *Am J Med Sci* **351**, 492-498, doi:10.1016/j.amjms.2016.02.035 (2016).
98 Chang, L. H. *et al.* UPSTROKE TIME PER CARDIAC CYCLE IS ASSOCIATED WITH CARDIOVASCULAR PROGNOSIS IN TYPE 2 DIABETES. *Endocr Pract* **25**, 1109-1116, doi:10.4158/ep-2019-0078 (2019).

99 Charlton-Menys, V. *et al.* Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). *Diabetologia* **52**, 218-225, doi:10.1007/s00125-008-1176-8 (2009).
100 Chen, H. S. *et al.* Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. *Diabet Med* **24**, 1336-1344, doi:10.1111/j.1464-5491.2007.02270.x (2007).
101 Chen, S. *et al.* The long-term effectiveness of metabolic control on cardiovascular disease in patients with diabetes in a real-world health care setting - A prospective diabetes management study. *Prim Care Diabetes* **14**, 274-281, doi:10.1016/j.pcd.2019.09.006 (2020).
102 Cheng, F. *et al.* Shortened relative leukocyte telomere length is associated with prevalent and incident cardiovascular complications in type 2 diabetes: Analysis from the Hong Kong Diabetes Register. *Diabetes Care* **43**, 2257-2265, doi:10.2337/dc20-0028 (2020).
103 Christensen, P. K. *et al.* QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes. *Scand J Clin Lab Invest* **60**, 323-332, doi:10.1080/003655100750046486 (2000).
104 Christiansen, M. S., Hommel, E., Magid, E. & Feldt-Rasmussen, B. Orosomucoid in urine predicts cardiovascular and over-all mortality in patients with Type II diabetes. *Diabetologia* **45**, 115-120, doi:10.1007/s125-002-8251-3 (2002).
105 Christiansen, M. S., Hommel, E., Magid, E. & Feldt-Rasmussen, B. Orosomucoid in urine is a powerful predictor of cardiovascular mortality in normoalbuminuric patients with type 2 diabetes at five years of follow-up. *Diabetologia* **48**, 386-393, doi:10.1007/s00125-004-1630-1 (2005).
106 Church, E. *et al.* Relationship between estimated glomerular filtration rate and incident cardiovascular disease in an ethnically diverse primary care cohort. *N Z Med J* **132**, 11-26 (2019).
107 Chyun, D. A. *et al.* Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. *SAGE Open Medicine* **3**, doi:10.1177/2050312114568476 (2015).
108 Cioffi, G. *et al.* Usefulness of subclinical left ventricular midwall dysfunction to predict cardiovascular mortality in patients with type 2 diabetes mellitus. *Am J Cardiol* **113**, 1409-1414, doi:10.1016/j.amjcard.2014.01.415 (2014).
109 Clarke, P. M. *et al.* A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). *Diabetologia* **47**, 1747-1759, doi:10.1007/s00125-004-1527-z (2004).
110 Clarke, P. M. *et al.* Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. *Med Care* **47**, 61-68, doi:10.1097/MLR.0b013e3181844855 (2009).
111 Cockcroft, J. R. *et al.* Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus. *Am J Hypertens* **18**, 1463-1467; discussion 1468, doi:10.1016/j.amjhyper.2005.05.009 (2005).
112 Colombo, M. *et al.* Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes. *Atherosclerosis* **274**, 182-190, doi:10.1016/j.atherosclerosis.2018.05.014 (2018).
113 Cortigiani, L. *et al.* Prognostic meaning of coronary microvascular disease in type 2 diabetes mellitus: a transthoracic Doppler echocardiographic study. *J Am Soc Echocardiogr* **27**, 742-748, doi:10.1016/j.echo.2014.02.010 (2014).

114 Cosson, E. *et al.* Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients. *Diabetes Care* **34**, 2101-2107, doi:10.2337/dc11-0480 (2011).
115 Cournot, M. *et al.* Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. *J Am Heart Assoc* **7**, doi:10.1161/jaha.117.007397 (2018).
116 Cox, A. J. *et al.* Prediction of mortality using a multi-bed vascular calcification score in the Diabetes Heart Study. *Cardiovasc Diabetol* **13**, 160, doi:10.1186/s12933-014-0160-5 (2014).
117 Cox, A. J. *et al.* Genetic risk score associations with cardiovascular disease and mortality in the Diabetes Heart Study. *Diabetes Care* **37**, 1157-1164, doi:10.2337/dc13-1514 (2014).
118 Cox, A. J. *et al.* Usefulness of biventricular volume as a predictor of mortality in patients with diabetes mellitus (from the Diabetes Heart Study). *Am J Cardiol* **111**, 1152-1158, doi:10.1016/j.amjcard.2012.12.044 (2013).
119 Cui, N. H., Yang, J. M., Liu, X. & Wang, X. B. Poly(ADP-Ribose) Polymerase Activity and Coronary Artery Disease in Type 2 Diabetes Mellitus: An Observational and Bidirectional Mendelian Randomization Study. *Arterioscler Thromb Vasc Biol* **40**, 2516-2526, doi:10.1161/ATVBAHA.120.314712 (2020).
120 Daka, B. *et al.* Low concentrations of serum testosterone predict acute myocardial infarction in men with type 2 diabetes mellitus. *BMC Endocr Disord* **15**, 35, doi:10.1186/s12902-015-0034-1 (2015).
121 Davis, T. M., Coleman, R. L. & Holman, R. R. Ethnicity and long-term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83). *Diabet Med* **31**, 200-207, doi:10.1111/dme.12353 (2014).
122 Davis, W. A., Colagiuri, S. & Davis, T. M. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. *Med J Aust* **190**, 180-184, doi:10.5694/j.1326-5377.2009.tb02684.x (2009).
123 Davis, W. A., Hellbusch, V., Hunter, M. L., Bruce, D. G. & Davis, T. M. E. Contemporary cardiovascular risk assessment for type 2 diabetes including heart failure as an outcome: The fremantle diabetes study phase ii. *Journal of Clinical Medicine* **9**, doi:10.3390/jcm9051428 (2020).
124 Davis, W. A., Knuiman, M. W. & Davis, T. M. An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. *Intern Med J* **40**, 286-292, doi:10.1111/j.1445-5994.2009.01958.x (2010).
125 Dayan, A. *et al.* Coronary calcium score, albuminuria and inflammatory markers in type 2 diabetic patients: associations and prognostic implications. *Diabetes Res Clin Pract* **98**, 98-103, doi:10.1016/j.diabres.2012.04.012 (2012).
126 de Galan, B. E. *et al.* Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. *Diabetologia* **52**, 2328-2336, doi:10.1007/s00125-009-1484-7 (2009).
127 De Lorenzo, A., Lima, R. S., Siqueira-Filho, A. G. & Pantoja, M. R. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic

patients with diabetes mellitus and no known coronary artery disease. *Am J Cardiol* **90**, 827-832, doi:10.1016/s0002-9149(02)02702-9 (2002).
128 de Santiago, A., García-Lledó, A., Ramos, E. & Santiago, C. [Prognostic value of ECGs in patients with type-2 diabetes mellitus without known cardiovascular disease]. *Rev Esp Cardiol* **60**, 1035-1041, doi:10.1157/13111235 (2007).
129 de Vries, T. I. *et al.* Normal-range thyroid-stimulating hormone levels and cardiovascular events and mortality in type 2 diabetes. *Diabetes Res Clin Pract* **157**, 107880, doi:10.1016/j.diabres.2019.107880 (2019).
130 Djaileb, L. *et al.* Prognostic value of SPECT myocardial perfusion entropy in high-risk type 2 diabetic patients. *Eur J Nucl Med Mol Imaging* **48**, 1813-1821, doi:10.1007/s00259-020-05110-4 (2021).
131 Doney, A. S. *et al.* The FTO gene is associated with an atherogenic lipid profile and myocardial infarction in patients with type 2 diabetes: a Genetics of Diabetes Audit and Research Study in Tayside Scotland (Go-DARTS) study. *Circ Cardiovasc Genet* **2**, 255-259, doi:10.1161/circgenetics.108.822320 (2009).
132 Doney, A. S., Lee, S., Leese, G. P., Morris, A. D. & Palmer, C. N. Increased cardiovascular morbidity and mortality in type 2 diabetes is associated with the glutathione S transferase theta-null genotype: a Go-DARTS study. *Circulation* **111**, 2927-2934, doi:10.1161/circulationaha.104.509224 (2005).
133 Doney, A. S. F. *et al.* Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: A Go-DARTS study. *Nuclear Receptor* **3**, doi:10.1186/1478-1336-3-4 (2005).
134 Donnan, P. T., Donnelly, L., New, J. P. & Morris, A. D. Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. *Diabetes Care* **29**, 1231-1236, doi:10.2337/dc05-1911 (2006).
135 Drinkwater, J. J. *et al.* Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle Diabetes Study Phase II. *Cardiovasc Diabetol* **19**, 43, doi:10.1186/s12933-020-01018-3 (2020).
136 Drury, P. L. *et al.* Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetologia* **54**, 32-43, doi:10.1007/s00125-010-1854-1 (2011).
137 Duan, J. G. *et al.* Long-term risk of cardiovascular disease among type 2 diabetic patients with asymptomatic intracranial atherosclerosis: a prospective cohort study. *PLoS One* **9**, e106623, doi:10.1371/journal.pone.0106623 (2014).
138 Duan, J. G. *et al.* Sex differences in epidemiology and risk factors of acute coronary syndrome in Chinese patients with type 2 diabetes: a long-term prospective cohort study. *PLoS One* **10**, e0122031, doi:10.1371/journal.pone.0122031 (2015).
139 Eguchi, K., Hoshide, S. & Kario, K. Target home morning SBP be below 125 mmHg in type 2 diabetes patients. *J Hypertens* **36**, 1284-1290, doi:10.1097/hjh.0000000000001683 (2018).
140 Eguchi, K. *et al.* Differential impact of left ventricular mass and relative wall thickness on cardiovascular prognosis in diabetic and nondiabetic hypertensive subjects. *Am Heart J* **154**, 79.e79-15, doi:10.1016/j.ahj.2007.04.021 (2007).

141 Eguchi, K. *et al.* Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. *Am J Hypertens* **22**, 46-51, doi:10.1038/ajh.2008.294 (2009).
142 Eguchi, K. *et al.* Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. *Am J Hypertens* **21**, 443-450, doi:10.1038/ajh.2008.4 (2008).
143 Eguchi, K. *et al.* Increased heart rate variability during sleep is a predictor for future cardiovascular events in patients with type 2 diabetes. *Hypertens Res* **33**, 737-742, doi:10.1038/hr.2010.61 (2010).
144 Eijkelkamp, W. B. *et al.* Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. *J Hypertens* **25**, 871-876, doi:10.1097/HJH.0b013e328014953c (2007).
145 Eliasson, B. *et al.* Clinical usefulness of different lipid measures for prediction of coronary heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register. *Diabetes Care* **34**, 2095-2100, doi:10.2337/dc11-0209 (2011).
146 Elkeles, R. S. *et al.* Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. *Eur Heart J* **29**, 2244-2251, doi:10.1093/eurheartj/ehn279 (2008).
147 Elley, C. R., Kenealy, T., Robinson, E. & Drury, P. L. Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. *Diabet Med* **25**, 1295-1301, doi:10.1111/j.1464-5491.2008.02581.x (2008).
148 Elley, C. R., Robinson, E., Kenealy, T., Bramley, D. & Drury, P. L. Derivation and validation of a new cardiovascular risk score for people with type 2 diabetes: the new zealand diabetes cohort study. *Diabetes Care* **33**, 1347-1352, doi:10.2337/dc09-1444 (2010).
149 Estacio, R. O., Dale, R. A., Schrier, R. & Krantz, M. J. Relation of reduction in urinary albumin excretion to ten-year cardiovascular mortality in patients with type 2 diabetes and systemic hypertension. *Am J Cardiol* **109**, 1743-1748, doi:10.1016/j.amjcard.2012.02.020 (2012).
150 Everett, B. M. *et al.* Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. *N Engl J Med* **373**, 610-620, doi:10.1056/NEJMoa1415921 (2015).
151 Fadini, G. P. *et al.* p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications. *Cardiovasc Diabetol* **17**, 16, doi:10.1186/s12933-018-0660-9 (2018).
152 Fadini, G. P., Rigato, M., Cappellari, R., Bonora, B. M. & Avogaro, A. Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+CD133+ Stem Cells in Patients With Type 2 Diabetes. *Diabetes Care* **40**, 125-131, doi:10.2337/dc16-1755 (2017).
153 Faghihi-Kashani, S. *et al.* Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes. *Diabetes Metab* **42**, 55-61, doi:10.1016/j.diabet.2015.10.001 (2016).
154 Faglia, E. *et al.* Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan Study on Atherosclerosis and Diabetes (MiSAD). *Diabetes Care* **25**, 2032-2036, doi:10.2337/diacare.25.11.2032 (2002).

155 Ferrarezi, D. A. *et al.* Allelic variations of the vitamin D receptor (VDR) gene are associated with increased risk of coronary artery disease in type 2 diabetics: the DIABHYCAR prospective study. *Diabetes Metab* **39**, 263-270, doi:10.1016/j.diabet.2012.11.004 (2013).
156 Filippella, M. *et al.* Ankle brachial pressure index usefulness as predictor factor for coronary heart disease in diabetic patients. *J Endocrinol Invest* **30**, 721-725, doi:10.1007/bf03350808 (2007).
157 Florkowski, C. M., Scott, R. S., Coope, P. A. & Moir, C. L. Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study. *Diabetes Res Clin Pract* **53**, 113-120, doi:10.1016/s0168-8227(01)00246-7 (2001).
158 Folsom, A. R., Chambless, L. E., Duncan, B. B., Gilbert, A. C. & Pankow, J. S. Prediction of coronary heart disease in middle-aged adults with diabetes. *Diabetes Care* **26**, 2777-2784, doi:10.2337/diacare.26.10.2777 (2003).
159 Fox, C. S., Sullivan, L., D'Agostino, R. B., Sr. & Wilson, P. W. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. *Diabetes Care* **27**, 704-708, doi:10.2337/diacare.27.3.704 (2004).
160 Fragoso, A., Mendes, F., Silva, A. P. & Neves, P. L. Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease. *J Diabetes Complications* **29**, 1098-1104, doi:10.1016/j.jdiacomp.2015.05.010 (2015).
161 Freemantle, N., Danchin, N., Calvi-Gries, F., Vincent, M. & Home, P. D. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. *Diabetes Obes Metab* **18**, 152-158, doi:10.1111/dom.12598 (2016).
162 Friedman, A. N., Hunsicker, L. G., Selhub, J. & Bostom, A. G. Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. *J Am Soc Nephrol* **16**, 3397-3402, doi:10.1681/asn.2004100846 (2005).
163 Fukushima, H. *et al.* Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. *J Am Coll Cardiol* **43**, 2219-2224, doi:10.1016/j.jacc.2003.09.074 (2004).
164 Fuller, J. H., Stevens, L. K. & Wang, S. L. Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. *Diabetologia* **44 Suppl 2**, S54-64, doi:10.1007/pl00002940 (2001).
165 Fumisawa, Y. *et al.* Systematic analysis of risk factors for coronary heart disease in Japanese patients with type 2 diabetes: a matched case-control study. *J Atheroscler Thromb* **19**, 918-923, doi:10.5551/jat.13334 (2012).
166 Gasior, M. *et al.* Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. *Cardiol J* **15**, 422-430 (2008).
167 Gazzaruso, C. *et al.* Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes: comparison with ankle-brachial index. *Diabetes Care* **36**, 1720-1725, doi:10.2337/dc12-1401 (2013).
168 Gazzaruso, C. *et al.* Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in Type 2 diabetic patients. *J Diabetes Complications* **17**, 135-140, doi:10.1016/s1056-8727(02)00192-7 (2003).
169 Gazzaruso, C. *et al.* Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a

potential protective role for statins and 5-phosphodiesterase inhibitors. *J Am Coll Cardiol* **51**, 2040-2044, doi:10.1016/j.jacc.2007.10.069 (2008).
170 Georgoulias, P. *et al.* Long-term prognostic value of heart-rate recovery after treadmill testing in patients with diabetes mellitus. *Int J Cardiol* **134**, 67-74, doi:10.1016/j.ijcard.2008.01.036 (2009).
171 Gimeno-Orna, J. A., Lou-Arnal, L. M., Boned-Juliani, B. & Molinero-Herguedas, E. Mild renal insufficiency as a cardiovascular risk factor in non-proteinuric type II diabetes. *Diabetes Res Clin Pract* **64**, 191-199, doi:10.1016/j.diabres.2003.10.018 (2004).
172 Giorda, C. B. *et al.* Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. *Diabetes Care* **31**, 2154-2159, doi:10.2337/dc08-1013 (2008).
173 Giovacchini, G. *et al.* Microalbuminuria predicts silent myocardial ischaemia in type 2 diabetes patients. *Eur J Nucl Med Mol Imaging* **40**, 548-557, doi:10.1007/s00259-012-2323-5 (2013).
174 Group, T. L. A. R. Prospective Association of GLUL rs10911021 With Cardiovascular Morbidity and Mortality Among Individuals With Type 2 Diabetes: The Look AHEAD Study. *Diabetes* **65**, 297-302, doi:10.2337/db15-0890 (2015).
175 Guzder, R. N., Gatling, W., Mullee, M. A. & Byrne, C. D. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. *Diabetologia* **49**, 49-55, doi:10.1007/s00125-005-0063-9 (2006).
176 Guzder, R. N., Gatling, W., Mullee, M. A., Mehta, R. L. & Byrne, C. D. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. *Diabet Med* **22**, 554-562, doi:10.1111/j.1464-5491.2005.01494.x (2005).
177 Hadaegh, F. *et al.* Electrocardiography-defined silent CHD and risk of cardiovascular events among diabetic patients in a Middle Eastern population. *Eur J Prev Cardiol* **19**, 1227-1233, doi:10.1177/1741826711428065 (2012).
178 Hadjadj, S. *et al.* Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete d. *Diabetes Care* **31**, 1847-1852, doi:10.2337/dc07-2079 (2008).
179 Hage, F. G. *et al.* The heart rate response to adenosine: a simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes. *Int J Cardiol* **167**, 2952-2957, doi:10.1016/j.ijcard.2012.08.011 (2013).
180 Halon, D. A. *et al.* Coronary Computed Tomography (CT) Angiography as a Predictor of Cardiac and Noncardiac Vascular Events in Asymptomatic Type 2 Diabetics: A 7-Year Population-Based Cohort Study. *J Am Heart Assoc* **5**, doi:10.1161/jaha.116.003226 (2016).
181 Halon, D. A. *et al.* Plaque Morphology as Predictor of Late Plaque Events in Patients With Asymptomatic Type 2 Diabetes: A Long-Term Observational Study. *JACC Cardiovasc Imaging* **12**, 1353-1363, doi:10.1016/j.jcmg.2018.02.025 (2019).
182 Hamada, S. & Gulliford, M. C. Multiple risk factor control, mortality and cardiovascular events in type 2 diabetes and chronic kidney disease: a population-based cohort study. *BMJ Open* **8**, e019950, doi:10.1136/bmjopen-2017-019950 (2018).

183 Hanefeld, M. *et al.* Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. *Diabetologia* **39**, 1577-1583, doi:10.1007/s001250050617 (1996).
184 Hata, J. *et al.* Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. *Circulation* **128**, 1325-1334, doi:10.1161/circulationaha.113.002717 (2013).
185 Hayashi, T. *et al.* Metabolic predictors of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age. *Cardiovasc Diabetol* **12**, 10, doi:10.1186/1475-2840-12-10 (2013).
186 Hayes, A. J., Leal, J., Gray, A. M., Holman, R. R. & Clarke, P. M. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. *Diabetologia* **56**, 1925-1933, doi:10.1007/s00125-013-2940-y (2013).
187 He, Q., Pan, J., Wang, L., Fang, Y. & Hu, R. Prospective study: Aldehyde dehydrogenase 2 gene is associated with cardio-cerebrovascular complications in type 2 diabetes patients. *J Diabetes Investig* **12**, 1845-1854, doi:10.1111/jdi.13538 (2021).
188 Heidari, B. *et al.* Assessment of serum 25-hydroxy vitamin D improves coronary heart disease risk stratification in patients with type 2 diabetes. *Am Heart J* **170**, 573-579.e575, doi:10.1016/j.ahj.2015.06.017 (2015).
189 Heijmans, B. T. *et al.* Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. *Atherosclerosis* **149**, 91-97, doi:10.1016/s0021-9150(99)00311-1 (2000).
190 Ho, J. S. *et al.* Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. *Diabetes Res Clin Pract* **97**, 483-491, doi:10.1016/j.diabres.2012.03.012 (2012).
191 Hoffmann, M. M., März, W., Genser, B., Drechsler, C. & Wanner, C. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. *Atherosclerosis* **219**, 659-662, doi:10.1016/j.atherosclerosis.2011.07.126 (2011).
192 Hong, L. F. *et al.* Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease. *Lipids Health Dis* **16**, 7, doi:10.1186/s12944-017-0410-0 (2017).
193 Howard, B. V. *et al.* LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. *Arterioscler Thromb Vasc Biol* **20**, 830-835, doi:10.1161/01.atv.20.3.830 (2000).
194 Hsieh, Y. T. *et al.* Subnormal Estimated Glomerular Filtration Rate Strongly Predict Incident Cardiovascular Events in Type 2 Diabetic Chinese Population With Normoalbuminuria. *Medicine (Baltimore)* **95**, e2200, doi:10.1097/md.0000000000002200 (2016).
195 Hu, C. P. *et al.* Platelet Distribution Width on Admission Predicts In-Stent Restenosis in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Treated with Percutaneous Coronary Intervention. *Chin Med J (Engl)* **131**, 757-763, doi:10.4103/0366-6999.228247 (2018).

196 Huang, X. H. *et al.* Angiotensin-converting enzyme gene polymorphism is associated with coronary heart disease in non-insulin-dependent diabetic patients evaluated for 9 years. *Metabolism* **47**, 1258-1262, doi:10.1016/s0026-0495(98)90333-x (1998).
197 Hunt, K. J. *et al.* Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort. *Diabetes Care* **41**, 840-846, doi:10.2337/dc17-2083 (2018).
198 Iijima, K. *et al.* Lower physical activity is a strong predictor of cardiovascular events in elderly patients with type 2 diabetes mellitus beyond traditional risk factors: the Japanese Elderly Diabetes Intervention Trial. *Geriatr Gerontol Int* **12 Suppl 1**, 77-87, doi:10.1111/j.1447-0594.2011.00815.x (2012).
199 Ikeda, Y. *et al.* Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. *Acta Diabetol* **46**, 239-242, doi:10.1007/s00592-008-0066-3 (2009).
200 Irie, Y. *et al.* The utility of ultrasonic tissue characterization of carotid plaque in the prediction of cardiovascular events in diabetic patients. *Atherosclerosis* **230**, 399-405, doi:10.1016/j.atherosclerosis.2013.08.015 (2013).
201 Jeevarethinam, A. *et al.* Usefulness of Carotid Plaques as Predictors of Obstructive Coronary Artery Disease and Cardiovascular Events in Asymptomatic Individuals With Diabetes Mellitus. *Am J Cardiol* **121**, 910-916, doi:10.1016/j.amjcard.2018.01.001 (2018).
202 Jha, D. *et al.* Prognostic role of soluble ST2 in acute coronary syndrome with diabetes. *Eur J Clin Invest* **48**, e12994, doi:10.1111/eci.12994 (2018).
203 Jiang, R. *et al.* Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. *Diabetes Care* **27**, 1991-1997, doi:10.2337/diacare.27.8.1991 (2004).
204 Jimenez-Corona, A. *et al.* Electrocardiographic abnormalities predict deaths from cardiovascular disease and ischemic heart disease in Pima Indians with type 2 diabetes. *Am Heart J* **151**, 1080-1086, doi:10.1016/j.ahj.2005.06.033 (2006).
205 Jin, J. L. *et al.* Triglyceride glucose and haemoglobin glycation index for predicting outcomes in diabetes patients with new-onset, stable coronary artery disease: a nested case-control study. *Ann Med* **50**, 576-586, doi:10.1080/07853890.2018.1523549 (2018).
206 Johnston, S. S. *et al.* Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. *Diabetes Care* **34**, 1164-1170, doi:10.2337/dc10-1915 (2011).
207 Juutilainen, A., Lehto, S., Suhonen, M., Rönnemaa, T. & Laakso, M. Thoracoabdominal calcifications predict cardiovascular disease mortality in type 2 diabetic and nondiabetic subjects: 18-year follow-up study. *Diabetes Care* **33**, 583-585, doi:10.2337/dc09-1813 (2010).
208 Kamoi, K., Ito, T., Miyakoshi, M. & Minagawa, S. Usefulness of home blood pressure measurement in the morning in patients with type 2 diabetes: long-term results of a prospective longitudinal study. *Clin Exp Hypertens* **32**, 184-192, doi:10.3109/10641960903254513 (2010).
209 Katakami, N. *et al.* Accumulation of oxidative stress-related gene polymorphisms and the risk of coronary heart disease events in patients with type 2 diabetes--an 8-year prospective study. *Atherosclerosis* **235**, 408-414, doi:10.1016/j.atherosclerosis.2014.05.936 (2014).

210 Katakami, N. *et al.* Clinical utility of brachial-ankle pulse wave velocity in the prediction of cardiovascular events in diabetic patients. *Cardiovasc Diabetol* **13**, 128, doi:10.1186/s12933-014-0128-5 (2014).
211 Katakami, N. *et al.* Ultrasonic tissue characterization of carotid plaque improves the prediction of cardiovascular events in diabetic patients: a pilot study. *Diabetes Care* **35**, 2640-2646, doi:10.2337/dc12-0331 (2012).
212 Kawasaki, R. *et al.* Risk of cardiovascular diseases is increased even with mild diabetic retinopathy: the Japan Diabetes Complications Study. *Ophthalmology* **120**, 574-582, doi:10.1016/j.ophtha.2012.08.029 (2013).
213 Keavney, B. D. *et al.* UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM. *Diabetologia* **38**, 948-952, doi:10.1007/BF00400584 (1995).
214 Keller, T. *et al.* Prognostic Value of High-Sensitivity Versus Conventional Cardiac Troponin T Assays Among Patients With Type 2 Diabetes Mellitus Undergoing Maintenance Hemodialysis. *Am J Kidney Dis* **71**, 822-830, doi:10.1053/j.ajkd.2017.10.016 (2018).
215 Kenealy, T. *et al.* An association between ethnicity and cardiovascular outcomes for people with Type 2 diabetes in New Zealand. *Diabet Med* **25**, 1302-1308, doi:10.1111/j.1464-5491.2008.02593.x (2008).
216 Kengne, A. P. *et al.* The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax. *Diabetologia* **53**, 821-831, doi:10.1007/s00125-010-1681-4 (2010).
217 Kengne, A. P. *et al.* Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. *Eur J Cardiovasc Prev Rehabil* **18**, 393-398, doi:10.1177/1741826710394270 (2011).
218 Khalili, S., Hatami, M., Hadaegh, F., Sheikholeslami, F. & Azizi, F. Prediction of cardiovascular events with consideration of general and central obesity measures in diabetic adults: results of the 8.4-year follow-up. *Metab Syndr Relat Disord* **10**, 218-224, doi:10.1089/met.2011.0070 (2012).
219 Kim, M. K. *et al.* Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus: A 10-year longitudinal cohort study. *J Diabetes Complications* **32**, 906-910, doi:10.1016/j.jdiacomp.2018.08.007 (2018).
220 Koch, M., Kutkuhn, B., Grabensee, B. & Ritz, E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. *Nephrol Dial Transplant* **12**, 2603-2611, doi:10.1093/ndt/12.12.2603 (1997).
221 Koo, B. K., Chung, W. Y. & Moon, M. K. Peripheral arterial endothelial dysfunction predicts future cardiovascular events in diabetic patients with albuminuria: a prospective cohort study. *Cardiovasc Diabetol* **19**, 82, doi:10.1186/s12933-020-01062-z (2020).
222 Kuricová, K. *et al.* NOS3 894G>T polymorphism is associated with progression of kidney disease and cardiovascular morbidity in type 2 diabetic patients: NOS3 as a modifier gene for diabetic nephropathy? *Kidney Blood Press Res* **38**, 92-98, doi:10.1159/000355757 (2013).

223 Lagani, V. *et al.* Development and validation of risk assessment models for diabetes-related complications based on the DCCT/EDIC data. *J Diabetes Complications* **29**, 479-487, doi:10.1016/j.jdiacomp.2015.03.001 (2015).
224 Lapin, B. R. *et al.* Pain in Patients With Type 2 Diabetes-Related Polyneuropathy Is Associated With Vascular Events and Mortality. *J Clin Endocrinol Metab* **105**, doi:10.1210/clinem/dgaa394 (2020).
225 Lau, K. K. *et al.* Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with type 2 diabetes. *Cardiovasc Diabetol* **11**, 101, doi:10.1186/1475-2840-11-101 (2012).
226 Le Feuvre, C. L. *et al.* Stress myocardial scintigraphy and dobutamine echocardiography in the detection of coronary disease in asymptomatic patients with type 2 diabetes. *Diabetes Metab* **31**, 135-142, doi:10.1016/s1262-3636(07)70179-9 (2005).
227 Lee, K. Y. *et al.* Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes. *Diabetes Care* **40**, 1241-1248, doi:10.2337/dc16-1844 (2017).
228 Lehto, S., Niskanen, L., Suhonen, M., Rönnemaa, T. & Laakso, M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. *Arterioscler Thromb Vasc Biol* **16**, 978-983, doi:10.1161/01.atv.16.8.978 (1996).
229 Lepojärvi, E. S. *et al.* Usefulness of Highly Sensitive Troponin as a Predictor of Short-Term Outcome in Patients With Diabetes Mellitus and Stable Coronary Artery Disease (from the ARTEMIS Study). *Am J Cardiol* **117**, 515-521, doi:10.1016/j.amjcard.2015.11.038 (2016).
230 Levy, A. P. *et al.* Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. *J Am Coll Cardiol* **40**, 1984-1990, doi:10.1016/s0735-1097(02)02534-2 (2002).
231 Li, P. I., Wang, J. N. & Guo, H. R. A long-term quality-of-care score for predicting the occurrence of macrovascular diseases in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* **139**, 72-80, doi:10.1016/j.diabres.2018.02.027 (2018).
232 Li, W. P. *et al.* Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus. *Cardiovasc Diabetol* **16**, 45, doi:10.1186/s12933-017-0526-6 (2017).
233 Liao, K. M. *et al.* Risk assessment of macrovascular and microvascular events in patients with type 2 diabetes by analyzing the amplitude variation of the fourth harmonic component of radial pulse wave. *Physiol Rep* **7**, e14252, doi:10.14814/phy2.14252 (2019).
234 Lièvre, M. M. *et al.* Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. *Trials* **12**, 23, doi:10.1186/1745-6215-12-23 (2011).
235 Lim, L. L. *et al.* Sudomotor dysfunction independently predicts incident cardiovascular-renal events and all-cause death in type 2 diabetes: the Joint Asia Diabetes Evaluation register. *Nephrol Dial Transplant* **34**, 1320-1328, doi:10.1093/ndt/gfy154 (2019).
236 Lim, S. *et al.* Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-

month prospective study. *Atherosclerosis* **196**, 398-404, doi:10.1016/j.atherosclerosis.2006.11.017 (2008).
237 Lin, C. H., Li, H. Y., Jiang, Y. D., Chang, T. J. & Chuang, L. M. Plasma YKL-40 predicts 10-year cardiovascular and all-cause mortality in individuals with type 2 diabetes. *Clin Endocrinol (Oxf)* **79**, 185-191, doi:10.1111/cen.12015 (2013).
238 Lin, E. H. *et al.* Depression and advanced complications of diabetes: a prospective cohort study. *Diabetes Care* **33**, 264-269, doi:10.2337/dc09-1068 (2010).
239 Lin, L. Y. *et al.* The ankle brachial index exhibits better association with cardiovascular outcomes than interarm systolic blood pressure difference in patients with type 2 diabetes. *Medicine (Baltimore)* **98**, e15556, doi:10.1097/md.0000000000015556 (2019).
240 Linnemann, B. & Janka, H. U. Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. *Exp Clin Endocrinol Diabetes* **111**, 215-222, doi:10.1055/s-2003-40466 (2003).
241 Linnemann, B., Voigt, W., Nobel, W. & Janka, H. U. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. *Exp Clin Endocrinol Diabetes* **114**, 127-134, doi:10.1055/s-2006-924012 (2006).
242 Lopes-Virella, M. F., Hunt, K. J., Baker, N. L., Virella, G. & Moritz, T. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. *Atherosclerosis* **224**, 526-531, doi:10.1016/j.atherosclerosis.2012.08.006 (2012).
243 Lorenzo-Almorós, A. *et al.* Galectin-3 is associated with cardiovascular events in post-acute coronary syndrome patients with type-2 diabetes. *Journal of Clinical Medicine* **9**, doi:10.3390/jcm9041105 (2020).
244 Lowe, G. *et al.* Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. *Diabetes* **63**, 1115-1123, doi:10.2337/db12-1625 (2014).
245 Lu, T. M., Lin, S. J., Lin, M. W., Hsu, C. P. & Chung, M. Y. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. *Cardiovasc Diabetol* **10**, 16, doi:10.1186/1475-2840-10-16 (2011).
246 Lu, W. *et al.* Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. *Diabetes Care* **26**, 16-23, doi:10.2337/diacare.26.1.16 (2003).
247 Lutgers, H. L. *et al.* Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. *Diabetologia* **52**, 789-797, doi:10.1007/s00125-009-1308-9 (2009).
248 Masi, S. *et al.* Telomere length, antioxidant status and incidence of ischaemic heart disease in type 2 diabetes. *Int J Cardiol* **216**, 159-164, doi:10.1016/j.ijcard.2016.04.130 (2016).
249 Massardo, T. *et al.* Factors associated with silent myocardial ischemia, autonomic or peripheral neuropathies, and survival in diabetes mellitus type 2 patients without cardiovascular symptoms. *International Journal of Diabetes in Developing Countries* **40**, 80-86, doi:10.1007/s13410-019-00758-7 (2020).
250 McEwan, P., Bennett, H., Ward, T. & Bergenheim, K. Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK. *Pharmacoeconomics* **33**, 149-161, doi:10.1007/s40273-014-0225-z (2015).

251 McMurray, J. J. *et al.* Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). *Am Heart J* **162**, 748-755.e743, doi:10.1016/j.ahj.2011.07.016 (2011).
252 Meerwaldt, R. *et al.* Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. *Diabetes Care* **30**, 107-112, doi:10.2337/dc06-1391 (2007).
253 Mellbin, L. G. *et al.* Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial. *Diabetes Care* **33**, 1604-1606, doi:10.2337/dc10-0088 (2010).
254 Mentz, R. J. *et al.* Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. *J Am Heart Assoc* **7**, e009304, doi:10.1161/jaha.118.009304 (2018).
255 Mohammedi, K. *et al.* Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. *Cardiovasc Diabetol* **14**, 845, doi:10.1186/s12933-014-0163-2 (2015).
256 Mohammedi, K. *et al.* Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes. *Diabetes Care* **39**, 2270-2277, doi:10.2337/dc16-1594 (2016).
257 Monseu, M. *et al.* Acute Kidney Injury Predicts Major Adverse Outcomes in Diabetes: Synergic Impact With Low Glomerular Filtration Rate and Albuminuria. *Diabetes Care* **38**, 2333-2340, doi:10.2337/dc15-1222 (2015).
258 Moosaie, F. *et al.* Lp(a) and Apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: A case-cohort study. *Nutr Metab Cardiovasc Dis* **30**, 1723-1731, doi:10.1016/j.numecd.2020.05.011 (2020).
259 Morieri, M. L. *et al.* Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. *Diabetes Care* **41**, 2404-2413, doi:10.2337/dc18-0709 (2018).
260 Morrish, N. J., Stevens, L. K., Fuller, J. H., Jarrett, R. J. & Keen, H. Risk factors for macrovascular disease in diabetes mellitus: the London follow-up to the WHO Multinational Study of Vascular Disease in Diabetics. *Diabetologia* **34**, 590-594, doi:10.1007/bf00400279 (1991).
261 Mukamal, K. J. *et al.* Prediction and classification of cardiovascular disease risk in older adults with diabetes. *Diabetologia* **56**, 275-283, doi:10.1007/s00125-012-2772-1 (2013).
262 Nag, S. *et al.* All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the South Tees Diabetes Mortality study. *Diabet Med* **24**, 10-17, doi:10.1111/j.1464-5491.2007.02023.x (2007).
263 Nagamachi, S. *et al.* Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. *J Nucl Cardiol* **13**, 34-42, doi:10.1016/j.nuclcard.2005.11.009 (2006).
264 Nakamura, M. *et al.* Brachial-ankle pulse wave velocity as a risk stratification index for the short-term prognosis of type 2 diabetic patients with coronary artery disease. *Hypertens Res* **33**, 1018-1024, doi:10.1038/hr.2010.126 (2010).

265 Nam, G. E. *et al.* Body Weight Variability and the Risk of Cardiovascular Outcomes and Mortality in Patients With Type 2 Diabetes: A Nationwide Cohort Study. *Diabetes Care* **43**, 2234-2241, doi:10.2337/dc19-2552 (2020).
266 Nargesi, A. A. *et al.* Nonlinear relation between pulse pressure and coronary heart disease in patients with type 2 diabetes or hypertension. *J Hypertens* **34**, 974-980, doi:10.1097/hjh.0000000000000866 (2016).
267 Nazimek-Siewniak, B., Moczulski, D. & Grzeszczak, W. Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design. *J Diabetes Complications* **16**, 271-276, doi:10.1016/s1056-8727(01)00184-2 (2002).
268 Ndrepepa, G. *et al.* Prognostic value of uric acid in patients with Type 2 diabetes mellitus and coronary artery disease. *Clin Sci (Lond)* **124**, 259-268, doi:10.1042/cs20120336 (2013).
269 Nelson, R. G. *et al.* Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. *Circulation* **81**, 987-995, doi:10.1161/01.cir.81.3.987 (1990).
270 Neves, A. L. *et al.* Allelic variations in superoxide dismutase-1 (SOD1) gene and renal and cardiovascular morbidity and mortality in type 2 diabetic subjects. *Mol Genet Metab* **106**, 359-365, doi:10.1016/j.ymgme.2012.04.023 (2012).
271 Nichols, G. A., Joshua-Gotlib, S. & Parasuraman, S. Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study. *J Gen Intern Med* **28**, 691-697, doi:10.1007/s11606-012-2320-1 (2013).
272 Nilsson, P. M. *et al.* Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register. *Eur J Cardiovasc Prev Rehabil* **16**, 506-512, doi:10.1097/HJR.0b013e32832ccc50 (2009).
273 Ningshen, R., Moathung Odyuo, Z., Arvind, G., Deba Singh, T. S. & Devi, B. A study of QTc interval prolongation as an independent predictor of cardiac mortality in type 2 diabetes mellitus. *JMS - Journal of Medical Society* **26**, 21-25 (2012).
274 Niskanen, L., Turpeinen, A., Penttilä, I. & Uusitupa, M. I. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. *Diabetes Care* **21**, 1861-1869, doi:10.2337/diacare.21.11.1861 (1998).
275 Niskanen, L. K., Penttilã, I., Parviainen, M. & Uusitupa, M. I. Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. *Diabetes Care* **19**, 486-493, doi:10.2337/diacare.19.5.486 (1996).
276 Nitenberg, A. *et al.* Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study. *Atherosclerosis* **183**, 113-120, doi:10.1016/j.atherosclerosis.2005.02.030 (2005).
277 Novo-Rodríguez, C. *et al.* Circulating levels of sclerostin are associated with cardiovascular mortality. *PLoS One* **13**, e0199504, doi:10.1371/journal.pone.0199504 (2018).
278 Odeberg, J., Larsson, C. A., Råstam, L. & Lindblad, U. The Asp298 allele of endothelial nitric oxide synthase is a risk factor for myocardial infarction among patients with type 2 diabetes mellitus. *BMC Cardiovasc Disord* **8**, 36, doi:10.1186/1471-2261-8-36 (2008).

279 Oellgaard, J. *et al.* Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria. *J Diabetes Complications* **32**, 1133-1140, doi:10.1016/j.jdiacomp.2018.09.012 (2018).
280 Oliveira, J. L. *et al.* Prognostic value of exercise echocardiography in diabetic patients. *Cardiovasc Ultrasound* **7**, 24, doi:10.1186/1476-7120-7-24 (2009).
281 Ong, K. L. *et al.* The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. *Diabetologia* **58**, 464-473, doi:10.1007/s00125-014-3458-7 (2015).
282 Ong, K. L. *et al.* Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. *Diabetes Res Clin Pract* **169**, 108450, doi:10.1016/j.diabres.2020.108450 (2020).
283 Ortega Moreno, L. *et al.* Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. *Cardiovasc Diabetol* **15**, 17, doi:10.1186/s12933-016-0339-z (2016).
284 Oshima, M. *et al.* Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. *J Am Soc Nephrol* **31**, 2925-2936, doi:10.1681/asn.2020050723 (2020).
285 Otto, S. *et al.* Microembolization and myonecrosis during elective percutaneous coronary interventions in diabetic patients: an intracoronary Doppler ultrasound study with 2-year clinical follow-up. *Basic Res Cardiol* **107**, 289, doi:10.1007/s00395-012-0289-x (2012).
286 Pagidipati, N. J. *et al.* Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. *Am Heart J* **219**, 47-57, doi:10.1016/j.ahj.2019.09.016 (2020).
287 Panero, F. *et al.* Uric acid is not an independent predictor of cardiovascular mortality in type 2 diabetes: a population-based study. *Atherosclerosis* **221**, 183-188, doi:10.1016/j.atherosclerosis.2011.11.042 (2012).
288 Park, G. M. *et al.* Coronary computed tomographic angiographic findings in asymptomatic patients with type 2 diabetes mellitus. *Am J Cardiol* **113**, 765-771, doi:10.1016/j.amjcard.2013.11.028 (2014).
289 Peng, W. H. *et al.* Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients. *Clin Biochem* **42**, 1252-1259, doi:10.1016/j.clinbiochem.2009.04.017 (2009).
290 Peters, K. E., Chubb, S. A., Davis, W. A. & Davis, T. M. The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study. *PLoS One* **8**, e74355, doi:10.1371/journal.pone.0074355 (2013).
291 Petretta, M. *et al.* Transient ischemic dilation in patients with diabetes mellitus: prognostic value and effect on clinical outcome after coronary revascularization. *Circ Cardiovasc Imaging* **6**, 908-915, doi:10.1161/circimaging.113.000497 (2013).
292 Pfister, R., Cairns, R., Erdmann, E. & Schneider, C. A. Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study. *Diabet Med* **28**, 1206-1212, doi:10.1111/j.1464-5491.2011.03281.x (2011).

293 Pickup, J. C. & Mattock, M. B. Activation of the innate immune system as a predictor of cardiovascular mortality in Type 2 diabetes mellitus. *Diabet Med* **20**, 723-726, doi:10.1046/j.1464-5491.2003.00990.x (2003).
294 Piniés, J. A. *et al.* Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the Basque Country Prospective Complications and Mortality Study risk engine (BASCORE). *Diabetologia* **57**, 2324-2333, doi:10.1007/s00125-014-3370-1 (2014).
295 Pintó, X. *et al.* [Factors predictive of cardiovascular disease in patients with type-2 diabetes and hypercholesterolemia. ESODIAH study]. *Rev Esp Cardiol* **60**, 251-258 (2007).
296 Poon, P. Y., Szeto, C. C., Kwan, B. C., Chow, K. M. & Li, P. K. Relationship between beta1-adrenergic receptor polymorphisms and cardiovascular disease in patients with diabetic nephropathy. *Nephrology (Carlton)* **15**, 242-247, doi:10.1111/j.1440-1797.2009.01182.x (2010).
297 Poon, P. Y., Szeto, C. C., Kwan, B. C., Chow, K. M. & Li, P. K. Relationship between HSP70-2 A+1267G Polymorphism and Cardiovascular Events of Chinese Peritoneal Dialysis Patients. *Nephron Clin Pract* **128**, 153-158, doi:10.1159/000368237 (2014).
298 Porchay-Baldérelli, I. *et al.* The CETP TaqIB polymorphism is associated with the risk of sudden death in type 2 diabetic patients. *Diabetes Care* **30**, 2863-2867, doi:10.2337/dc07-0869 (2007).
299 Porchay-Baldérelli, I. *et al.* Relationships between common polymorphisms of adenosine triphosphate-binding cassette transporter A1 and high-density lipoprotein cholesterol and coronary heart disease in a population with type 2 diabetes mellitus. *Metabolism* **58**, 74-79, doi:10.1016/j.metabol.2008.08.009 (2009).
300 Prentice, J. C., Pizer, S. D. & Conlin, P. R. Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with Type 2 diabetes. *Diabetic Medicine* **33**, 1640-1648, doi:10.1111/dme.13166 (2016).
301 Qi, L. *et al.* The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. *Diabetes* **54**, 1607-1610, doi:10.2337/diabetes.54.5.1607 (2005).
302 Qi, L. *et al.* Genetic susceptibility to coronary heart disease in type 2 diabetes: 3 independent studies. *J Am Coll Cardiol* **58**, 2675-2682, doi:10.1016/j.jacc.2011.08.054 (2011).
303 Qi, L. *et al.* Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. *JAMA* **310**, 821-828, doi:10.1001/jama.2013.276305 (2013).
304 Qi, Q., Workalemahu, T., Zhang, C., Hu, F. B. & Qi, L. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. *Eur Heart J* **33**, 325-334, doi:10.1093/eurheartj/ehr350 (2012).
305 Qin, Z. *et al.* The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China. *Cardiovasc Diabetol* **19**, 23, doi:10.1186/s12933-020-0989-8 (2020).

306 Quan, J. *et al.* Risk Prediction Scores for Mortality, Cerebrovascular, and Heart Disease Among Chinese People With Type 2 Diabetes. *J Clin Endocrinol Metab* **104**, 5823-5830, doi:10.1210/jc.2019-00731 (2019).
307 Raghavan, S. *et al.* Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. *J Am Heart Assoc* **8**, e011295, doi:10.1161/jaha.118.011295 (2019).
308 Ramírez-Prado, D. *et al.* A four-year cardiovascular risk score for type 2 diabetic inpatients. *PeerJ* **2015**, doi:10.7717/peerj.984 (2015).
309 Rana, B. S. *et al.* QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. *Heart* **91**, 44-50, doi:10.1136/hrt.2003.017632 (2005).
310 Rasmussen, D. G. K. *et al.* Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria. *Diabetes Care* **41**, 1493-1500, doi:10.2337/dc17-2392 (2018).
311 Ravassa, S. *et al.* Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: a pilot study. *Free Radic Biol Med* **81**, 1-12, doi:10.1016/j.freeradbiomed.2015.01.002 (2015).
312 Rawshani, A. *et al.* Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med* **379**, 633-644, doi:10.1056/NEJMoa1800256 (2018).
313 Rawshani, A. *et al.* Association Between Socioeconomic Status and Mortality, Cardiovascular Disease, and Cancer in Patients With Type 2 Diabetes. *JAMA Intern Med* **176**, 1146-1154, doi:10.1001/jamainternmed.2016.2940 (2016).
314 Read, S. H. *et al.* Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. *Diabetes Care* **41**, 2010-2018, doi:10.2337/dc18-0578 (2018).
315 Reinhard, H. *et al.* Osteoprotegerin and mortality in type 2 diabetic patients. *Diabetes Care* **33**, 2561-2566, doi:10.2337/dc10-0858 (2010).
316 Resl, M. *et al.* Serum uric acid is related to cardiovascular events and correlates with N-terminal pro-B-type natriuretic peptide and albuminuria in patients with diabetes mellitus. *Diabet Med* **29**, 721-725, doi:10.1111/j.1464-5491.2011.03515.x (2012).
317 Resl, M. *et al.* Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes. *Heart* **102**, 1963-1968, doi:10.1136/heartjnl-2015-308949 (2016).
318 Rossi, M. C. *et al.* Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR study. *Diabetes Care* **34**, 347-352, doi:10.2337/dc10-1709 (2011).
319 Rotbain Curovic, V. *et al.* Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. *Acta Diabetol* **55**, 1143-1150, doi:10.1007/s00592-018-1205-0 (2018).
320 Roumeliotis, A. *et al.* Carotid intima-media thickness is an independent predictor of all-cause mortality and cardiovascular morbidity in patients with diabetes mellitus type 2 and chronic kidney disease. *Ren Fail* **41**, 131-138, doi:10.1080/0886022x.2019.1585372 (2019).
321 Roumeliotis, A. K. *et al.* Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy. *Int Urol Nephrol* **50**, 321-329, doi:10.1007/s11255-017-1755-z (2018).

322 Roumeliotis, S. *et al.* Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy. *J Diabetes Complications* **31**, 1527-1532, doi:10.1016/j.jdiacomp.2017.06.012 (2017).
323 Rozing, M. P. *et al.* Changes in HbA1c during the first six years after the diagnosis of Type 2 diabetes mellitus predict long-term microvascular outcomes. *PLoS One* **14**, e0225230, doi:10.1371/journal.pone.0225230 (2019).
324 Ruggenenti, P. *et al.* Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. *J Am Soc Nephrol* **23**, 1717-1724, doi:10.1681/asn.2012030252 (2012).
325 Russo, G. T. *et al.* Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study. *Acta Diabetol* **48**, 95-101, doi:10.1007/s00592-009-0169-5 (2011).
326 Rutter, M. K., Wahid, S. T., McComb, J. M. & Marshall, S. M. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. *J Am Coll Cardiol* **40**, 56-61, doi:10.1016/s0735-1097(02)01910-1 (2002).
327 Rådholm, K. *et al.* The impact of using sagittal abdominal diameter to predict major cardiovascular events in European patients with type 2 diabetes. *Nutr Metab Cardiovasc Dis* **27**, 418-422, doi:10.1016/j.numecd.2017.02.001 (2017).
328 Rørth, R. *et al.* The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. *Eur J Heart Fail* **21**, 40-49, doi:10.1002/ejhf.1359 (2019).
329 Saely, C. H. *et al.* The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. *J Clin Endocrinol Metab* **90**, 5698-5703, doi:10.1210/jc.2005-0799 (2005).
330 Saely, C. H. *et al.* Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. *Eur J Clin Invest* **36**, 91-97, doi:10.1111/j.1365-2362.2006.01604.x (2006).
331 Saito, I. *et al.* Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. *Ann Intern Med* **133**, 81-91, doi:10.7326/0003-4819-133-2-200007180-00007 (2000).
332 Sakai, K. *et al.* Small dense low-density lipoprotein cholesterol is a promising biomarker for secondary prevention in older men with stable coronary artery disease. *Geriatr Gerontol Int* **18**, 965-972, doi:10.1111/ggi.13287 (2018).
333 Salles, G. F., Leite, N. C., Pereira, B. B., Nascimento, E. M. & Cardoso, C. R. Prognostic impact of clinic and ambulatory blood pressure components in high-risk type 2 diabetic patients: the Rio de Janeiro Type 2 Diabetes Cohort Study. *J Hypertens* **31**, 2176-2186, doi:10.1097/HJH.0b013e328364103f (2013).
334 Satirapoj, B., Tasanavipas, P. & Supasyndh, O. Role of TCF7L2 and PPARG2 Gene Polymorphisms in Renal and Cardiovascular Complications among Patients with Type 2 Diabetes: A Cohort Study. *Kidney Diseases* **5**, 220-227, doi:10.1159/000497100 (2019).
335 Saulnier, P. J. *et al.* Urinary Sodium Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality in a Type 2 Diabetes Cohort Population. *J Diabetes Res* **2017**, 5327352, doi:10.1155/2017/5327352 (2017).

336 Savonitto, S. *et al.* Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. *Diab Vasc Dis Res* **15**, 14-23, doi:10.1177/1479164117735493 (2018).
337 Schimke, K., Chubb, S. A. P., Davis, W. A. & Davis, T. M. E. Helicobacter pylori cytotoxin-associated gene-A antibodies do not predict complications or death in type 2 diabetes: The Fremantle Diabetes Study. *Atherosclerosis* **212**, 321-326, doi:10.1016/j.atherosclerosis.2010.05.021 (2010).
338 Schulze, M. B. *et al.* C-reactive protein and incident cardiovascular events among men with diabetes. *Diabetes Care* **27**, 889-894, doi:10.2337/diacare.27.4.889 (2004).
339 Schulze, M. B. *et al.* Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes. *Diabetologia* **47**, 2129-2136, doi:10.1007/s00125-004-1593-2 (2004).
340 Scirica, B. M. *et al.* Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: A secondary analysis of a randomized clinical trial. *JAMA Cardiology* **1**, 989-998, doi:10.1001/jamacardio.2016.3030 (2016).
341 Scirica, B. M. *et al.* Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. *JAMA Cardiol* **3**, 155-163, doi:10.1001/jamacardio.2017.4228 (2018).
342 Seferovic, J. P. *et al.* Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. *J Diabetes Res* **2018**, 1631263, doi:10.1155/2018/1631263 (2018).
343 Seyoum, B., Estacio, R. O., Berhanu, P. & Schrier, R. W. Exercise capacity is a predictor of cardiovascular events in patients with type 2 diabetes mellitus. *Diab Vasc Dis Res* **3**, 197-201, doi:10.3132/dvdr.2006.030 (2006).
344 Shao, H., Fonseca, V., Stoecker, C., Liu, S. & Shi, L. Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). *Pharmacoeconomics* **36**, 1125-1134, doi:10.1007/s40273-018-0662-1 (2018).
345 Shao, H., Shi, L. & Fonseca, V. A. Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors. *Diabetes Care* **43**, 1530-1536, doi:10.2337/dc20-0227 (2020).
346 Sharma, A. *et al.* Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. *Diabetes Care* **40**, 1763-1770, doi:10.2337/dc17-1091 (2017).
347 Sharma, A. *et al.* Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. *J Am Heart Assoc* **9**, e012797, doi:10.1161/jaha.119.012797 (2020).
348 Shin, S. H. *et al.* Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. *Eur J Heart Fail* **22**, 1133-1143, doi:10.1002/ejhf.1790 (2020).
349 Siddique, A. *et al.* Relationship of mildly increased albuminuria and coronary artery revascularization outcomes in patients with diabetes. *Catheter Cardiovasc Interv* **93**, E217-e224, doi:10.1002/ccd.27890 (2019).

350 Sidorenkov, G., Voorham, J., de Zeeuw, D., Haaijer-Ruskamp, F. M. & Denig, P. Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes? *PLoS One* **8**, e78821, doi:10.1371/journal.pone.0078821 (2013).
351 Silva, A. P. *et al.* Phosphorus as an early marker of morbidity and mortality in type 2 chronic kidney disease diabetic patients. *J Diabetes Complications* **27**, 328-332, doi:10.1016/j.jdiacomp.2013.02.007 (2013).
352 Silva, A. P. *et al.* What is the role of apelin regarding cardiovascular risk and progression of renal disease in type 2 diabetic patients with diabetic nephropathy? *Biomed Res Int* **2013**, 247649, doi:10.1155/2013/247649 (2013).
353 Simmons, R. K. *et al.* Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC-Norfolk Cohort. *Diabetes Care* **32**, 708-713, doi:10.2337/dc08-1918 (2009).
354 Smáradóttir, M. I. *et al.* Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort. *Diab Vasc Dis Res* **16**, 22-27, doi:10.1177/1479164118804451 (2019).
355 So, W. Y. *et al.* Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients. *Diabetes Care* **31**, 2148-2153, doi:10.2337/dc08-0712 (2008).
356 Soejima, H. *et al.* Proteinuria is independently associated with the incidence of primary cardiovascular events in diabetic patients. *J Cardiol* **75**, 387-393, doi:10.1016/j.jjcc.2019.08.021 (2020).
357 Soinio, M., Marniemi, J., Laakso, M., Lehto, S. & Rönnemaa, T. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. *Ann Intern Med* **140**, 94-100, doi:10.7326/0003-4819-140-2-200401200-00009 (2004).
358 Sone, H. *et al.* Waist circumference as a cardiovascular and metabolic risk in Japanese patients with type 2 diabetes. *Obesity (Silver Spring)* **17**, 585-592, doi:10.1038/oby.2008.481 (2009).
359 Sone, H. *et al.* Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study. *Diabetes Care* **35**, 1150-1157, doi:10.2337/dc11-1412 (2012).
360 Sone, H. *et al.* Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). *J Clin Endocrinol Metab* **96**, 3448-3456, doi:10.1210/jc.2011-0622 (2011).
361 Sone, H. *et al.* Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDCS). *Diabetologia* **56**, 1021-1030, doi:10.1007/s00125-012-2810-z (2013).
362 Spoelstra-de Man, A. M., Brouwer, C. B., Stehouwer, C. D. & Smulders, Y. M. Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria. *Diabetes Care* **24**, 2097-2101, doi:10.2337/diacare.24.12.2097 (2001).

363 Standl, E. *et al.* Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. *Diabetologia* **39**, 1540-1545, doi:10.1007/s001250050612 (1996).
364 Stehouwer, C. D., Gall, M. A., Hougaard, P., Jakobs, C. & Parving, H. H. Plasma homocysteine concentration predicts mortality in non-insulin-dependent diabetic patients with and without albuminuria. *Kidney Int* **55**, 308-314, doi:10.1046/j.1523-1755.1999.00256.x (1999).
365 Stevens, R. J., Kothari, V., Adler, A. I. & Stratton, I. M. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). *Clin Sci (Lond)* **101**, 671-679 (2001).
366 Strojek, K. *et al.* Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction. *J Clin Endocrinol Metab* **101**, 243-253, doi:10.1210/jc.2015-1962 (2016).
367 Sultan, A. *et al.* Myocardial perfusion imaging and cardiac events in a cohort of asymptomatic patients with diabetes living in southern France. *Diabet Med* **23**, 410-418, doi:10.1111/j.1464-5491.2006.01818.x (2006).
368 Svendstrup, M., Christiansen, M. S., Magid, E., Hommel, E. & Feldt-Rasmussen, B. Increased orosomucoid in urine is an independent predictor of cardiovascular and all-cause mortality in patients with type 2 diabetes at 10 years of follow-up. *J Diabetes Complications* **27**, 570-575, doi:10.1016/j.jdiacomp.2013.05.008 (2013).
369 Svensson, E. *et al.* Early Glycemic Control and Magnitude of HbA(1c) Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators. *Diabetes Care* **40**, 800-807, doi:10.2337/dc16-2271 (2017).
370 Svensson, M. K., Cederholm, J., Eliasson, B., Zethelius, B. & Gudbjörnsdottir, S. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. *Diab Vasc Dis Res* **10**, 520-529, doi:10.1177/1479164113500798 (2013).
371 Takao, T., Suka, M., Yanagisawa, H. & Iwamoto, Y. Impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all-cause mortality in patients with type 2 diabetes. *J Diabetes Investig* **8**, 600-608, doi:10.1111/jdi.12610 (2017).
372 Tan, X. & Benedict, C. Increased risk of myocardial infarction among patients with type 2 diabetes who carry the common rs10830963 variant in the MTNR1B gene. *Diabetes Care* **43**, 2289-2292, doi:10.2337/dc20-0507 (2020).
373 Tanaka, S. *et al.* Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. *Diabetes Care* **36**, 1193-1199, doi:10.2337/dc12-0958 (2013).
374 Thanyasiri, P., Celermajer, D. S. & Adams, M. R. Predictors of long-term outcome following percutaneous coronary intervention in patients with type 2 diabetes mellitus. *Coron Artery Dis* **17**, 131-138, doi:10.1097/00019501-200603000-00006 (2006).
375 The Look, A. R. G. Prospective association of a genetic risk score and lifestyle intervention with cardiovascular morbidity and mortality among individuals with type 2 diabetes: the Look AHEAD randomised controlled trial. *Diabetologia* **58**, 1803-1813, doi:10.1007/s00125-015-3610-z (2015).

376 Theilade, S. *et al.* Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). *J Hum Hypertens* **30**, 46-52, doi:10.1038/jhh.2015.22 (2016).
377 Thomas, M. C. *et al.* Relationship Between Plasma 8-OH-Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial. *J Am Heart Assoc* **7**, doi:10.1161/jaha.117.008226 (2018).
378 Tian, P., Zheng, X., Li, M., Li, W. & Niu, Q. Long-term prognostic value of coronary computed tomography angiography for asymptomatic patients with cad in type 2 diabetes mellitus. *Experimental and Therapeutic Medicine* **18**, 747-754, doi:10.3892/etm.2019.7593 (2019).
379 Ting, R. Z. *et al.* Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study. *Cardiovasc Diabetol* **9**, 77, doi:10.1186/1475-2840-9-77 (2010).
380 Tobias, D. K. *et al.* Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. *Circ Genom Precis Med* **11**, e002157, doi:10.1161/circgen.118.002157 (2018).
381 Turner, R. C. *et al.* Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). *Bmj* **316**, 823-828, doi:10.1136/bmj.316.7134.823 (1998).
382 Twito, O. *et al.* New-onset diabetes in elderly subjects: association between HbA1c levels, mortality, and coronary revascularization. *Diabetes Care* **36**, 3425-3429, doi:10.2337/dc12-2503 (2013).
383 Umamahesh, K., Vigneswari, A., Surya Thejaswi, G., Satyavani, K. & Viswanathan, V. Incidence of cardiovascular diseases and associated risk factors among subjects with type 2 diabetes - an 11-year follow up study. *Indian Heart J* **66**, 5-10, doi:10.1016/j.ihj.2013.12.009 (2014).
384 Valmadrid, C. T., Klein, R., Moss, S. E. & Klein, B. E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. *Arch Intern Med* **160**, 1093-1100, doi:10.1001/archinte.160.8.1093 (2000).
385 Valoti, E. *et al.* Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. *Front Genet* **10**, 681, doi:10.3389/fgene.2019.00681 (2019).
386 van der Heijden, A. A., Ortegon, M. M., Niessen, L. W., Nijpels, G. & Dekker, J. M. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. *Diabetes Care* **32**, 2094-2098, doi:10.2337/dc09-0745 (2009).
387 van der Leeuw, J. *et al.* Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus. *J Am Heart Assoc* **5**, doi:10.1161/JAHA.115.003048 (2016).
388 van der Leeuw, J. *et al.* The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus. *Heart* **101**, 222-229, doi:10.1136/heartjnl-2014-306068 (2015).

389 van Dieren, S. *et al.* External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. *Diabetologia* **54**, 264-270, doi:10.1007/s00125-010-1960-0 (2011).
390 Vanzetto, G. *et al.* Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. *Diabetes Care* **22**, 19-26, doi:10.2337/diacare.22.1.19 (1999).
391 Vavruch, C. *et al.* Using proximity extension proteomics assay to discover novel biomarkers associated with circulating leptin levels in patients with type 2 diabetes. *Sci Rep* **10**, 13097, doi:10.1038/s41598-020-69473-2 (2020).
392 Velho, G. *et al.* Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. *Cardiovasc Diabetol* **17**, 110, doi:10.1186/s12933-018-0753-5 (2018).
393 Vengen, I. T., Dale, A. C., Wiseth, R., Midthjell, K. & Videm, V. Lactoferrin is a novel predictor of fatal ischemic heart disease in diabetes mellitus type 2: long-term follow-up of the HUNT 1 study. *Atherosclerosis* **212**, 614-620, doi:10.1016/j.atherosclerosis.2010.06.008 (2010).
394 Venskutonyte, L., Brismar, K., Öhrvik, J., Rydén, L. & Kjellström, B. Self-rated health predicts outcome in patients with type 2 diabetes and myocardial infarction: a DIGAMI 2 quality of life sub-study. *Diab Vasc Dis Res* **10**, 361-367, doi:10.1177/1479164113482694 (2013).
395 Venskutonyte, L., Malmberg, K., Norhammar, A., Wedel, H. & Rydén, L. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes. *J Intern Med* **268**, 75-82, doi:10.1111/j.1365-2796.2010.02215.x (2010).
396 Venuraju, S. M. *et al.* Duration of type 2 diabetes mellitus and systolic blood pressure as determinants of severity of coronary stenosis and adverse events in an asymptomatic diabetic population: PROCEED study. *Cardiovasc Diabetol* **18**, 51, doi:10.1186/s12933-019-0855-8 (2019).
397 Venuraju, S. M. *et al.* Association of Epicardial Fat Volume With the Extent of Coronary Atherosclerosis and Cardiovascular Adverse Events in Asymptomatic Patients With Diabetes. *Angiology* **72**, 442-450, doi:10.1177/0003319720984607 (2021).
398 Venäläinen, M. S., Klén, R., Mahmoudian, M., Raitakari, O. T. & Elo, L. L. Easy-to-use tool for evaluating the elevated acute kidney injury risk against reduced cardiovascular disease risk during intensive blood pressure control. *J Hypertens* **38**, 511-518, doi:10.1097/hjh.0000000000002282 (2020).
399 Vepsäläinen, T. *et al.* Proteinuria modifies the effect of systolic blood pressure on total and cardiovascular disease mortality in patients with type 2 diabetes. *J Intern Med* **272**, 611-619, doi:10.1111/j.1365-2796.2012.02581.x (2012).
400 von Scholten, B. J. *et al.* Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. *Cardiovasc Diabetol* **14**, 59, doi:10.1186/s12933-015-0225-0 (2015).
401 von Scholten, B. J. *et al.* Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria. *Diabetologia* **59**, 1549-1557, doi:10.1007/s00125-016-3937-0 (2016).

402 von Scholten, B. J. *et al.* Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. *J Diabetes Complications* **30**, 248-255, doi:10.1016/j.jdiacomp.2015.11.005 (2016).
403 Wallander, M. *et al.* IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. *Diabetes Care* **30**, 2343-2348, doi:10.2337/dc07-0825 (2007).
404 Wan, E. Y., Fong, D. Y., Fung, C. S. & Lam, C. L. Incidence and predictors for cardiovascular disease in Chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study. *J Diabetes Complications* **30**, 444-450, doi:10.1016/j.jdiacomp.2015.12.010 (2016).
405 Wan, E. Y. F. *et al.* Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: A population-based retrospective cohort study. *Diabetes Obes Metab* **20**, 309-318, doi:10.1111/dom.13066 (2018).
406 Wang, Y. *et al.* Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes--an 8-year prospective cohort analysis of 1297 patients. *Diabet Med* **27**, 376-383, doi:10.1111/j.1464-5491.2010.02980.x (2010).
407 Wang, Y. *et al.* Prognostic effect of insertion/deletion polymorphism of the ace gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. *Diabetes Care* **28**, 348-354, doi:10.2337/diacare.28.2.348 (2005).
408 Watson, C. *et al.* Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up prog. *BMC Cardiovasc Disord* **21**, 87, doi:10.1186/s12872-021-01860-7 (2021).
409 Wei, M., Gaskill, S. P., Haffner, S. M. & Stern, M. P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. *Diabetes Care* **21**, 1167-1172, doi:10.2337/diacare.21.7.1167 (1998).
410 Wells, B. J. *et al.* Prediction of morbidity and mortality in patients with type 2 diabetes. *PeerJ* **2013**, doi:10.7717/peerj.87 (2013).
411 Wijkman, M., Länne, T., Östgren, C. J. & Nystrom, F. H. Aortic pulse wave velocity predicts incident cardiovascular events in patients with type 2 diabetes treated in primary care. *J Diabetes Complications* **30**, 1223-1228, doi:10.1016/j.jdiacomp.2016.06.008 (2016).
412 Wijkman, M., Länne, T., Östgren, C. J. & Nystrom, F. H. Diastolic orthostatic hypertension and cardiovascular prognosis in type 2 diabetes: a prospective cohort study. *Cardiovasc Diabetol* **15**, 83, doi:10.1186/s12933-016-0399-0 (2016).
413 Winkler, K. *et al.* Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus. *Atherosclerosis* **208**, 197-202, doi:10.1016/j.atherosclerosis.2009.06.036 (2010).
414 Wolsk, E. *et al.* Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. *J Am Heart Assoc* **6**, doi:10.1161/jaha.116.004743 (2017).

415 Wong, Y. K. *et al.* High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus. *Cardiovasc Diabetol* **18**, 171, doi:10.1186/s12933-019-0974-2 (2019).
416 Woodward, M. *et al.* Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. *Diabetes Obes Metab* **18**, 289-294, doi:10.1111/dom.12614 (2016).
417 Yamada, T., Itoi, T., Kiuchi, Y., Nemoto, M. & Yamashita, S. Proliferative diabetic retinopathy is a predictor of coronary artery disease in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract* **96**, e4-6, doi:10.1016/j.diabres.2011.12.007 (2012).
418 Yamasaki, Y. *et al.* Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. *Diabetes Care* **23**, 1310-1315, doi:10.2337/diacare.23.9.1310 (2000).
419 Yang, F., Ye, J., Pomerantz, K. & Stewart, M. Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* **6**, 247-256, doi:10.2147/DMSO.S43724 (2013).
420 Yang, G. R. *et al.* Association between Neck Circumference and the Occurrence of Cardiovascular Events in Type 2 Diabetes: Beijing Community Diabetes Study 20 (BCDS-20). *Biomed Res Int* **2019**, 4242304, doi:10.1155/2019/4242304 (2019).
421 Yang, S. H. *et al.* Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular Events in Diabetics With Coronary Artery Disease. *Am J Med Sci* **354**, 117-124, doi:10.1016/j.amjms.2017.03.032 (2017).
422 Yang, S. H. *et al.* Serum fibrinogen and cardiovascular events in Chinese patients with type 2 diabetes and stable coronary artery disease: a prospective observational study. *BMJ Open* **7**, e015041, doi:10.1136/bmjopen-2016-015041 (2017).
423 Yang, X. *et al.* Impacts of chronic kidney disease and albuminuria on associations between coronary heart disease and its traditional risk factors in type 2 diabetic patients - the Hong Kong diabetes registry. *Cardiovasc Diabetol* **6**, 37, doi:10.1186/1475-2840-6-37 (2007).
424 Yang, X. *et al.* Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. *Am J Cardiol* **101**, 596-601, doi:10.1016/j.amjcard.2007.10.019 (2008).
425 Yang, Z. K. *et al.* Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. *Int J Cardiol* **197**, 241-247, doi:10.1016/j.ijcard.2015.06.003 (2015).
426 Yeboah, J. *et al.* Development of a new diabetes risk prediction tool for incident coronary heart disease events: the Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. *Atherosclerosis* **236**, 411-417, doi:10.1016/j.atherosclerosis.2014.07.035 (2014).
427 Yeboah, P., Hsu, F. C., Bertoni, A. G. & Yeboah, J. Body Mass Index, Change in Weight, Body Weight Variability and Outcomes in Type 2 Diabetes Mellitus (from the ACCORD Trial). *Am J Cardiol* **123**, 576-581, doi:10.1016/j.amjcard.2018.11.016 (2019).
428 Yiu, K. H. *et al.* Predictive value of high-sensitivity troponin-I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus. *Cardiovasc Diabetol* **13**, 63, doi:10.1186/1475-2840-13-63 (2014).

429 Yoshida, M. *et al.* Combination of the Framingham risk score and carotid intima-media thickness improves the prediction of cardiovascular events in patients with type 2 diabetes. *Diabetes Care* **35**, 178-180, doi:10.2337/dc11-1333 (2012).
430 Yoshimura, T. *et al.* Low blood flow estimates in lower-leg arteries predict cardiovascular events in Japanese patients with type 2 diabetes with normal ankle-brachial indexes. *Diabetes Care* **29**, 1884-1890, doi:10.2337/dc06-0142 (2006).
431 Young, J. B. *et al.* Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. *Cardiovasc Diabetol* **17**, 118, doi:10.1186/s12933-018-0759-z (2018).
432 Yu, D. *et al.* Development and External Validation of Risk Scores for Cardiovascular Hospitalization and Rehospitalization in Patients With Diabetes. *J Clin Endocrinol Metab* **103**, 1122-1129, doi:10.1210/jc.2017-02293 (2018).
433 Yu, D. *et al.* Total/high density lipoprotein cholesterol and cardiovascular disease (re)hospitalization nadir in type 2 diabetes. *J Lipid Res* **59**, 1745-1750, doi:10.1194/jlr.P084269 (2018).
434 Yu, D. *et al.* Derivation and external validation of a risk prediction algorithm to estimate future risk of cardiovascular death among patients with type 2 diabetes and incident diabetic nephropathy: prospective cohort study. *BMJ Open Diabetes Res Care* **7**, e000735, doi:10.1136/bmjdrc-2019-000735 (2019).
435 Yu, D. & Simmons, D. Relationship between HbA1c and risk of all-cause hospital admissions among people with Type 2 diabetes. *Diabetic Medicine* **30**, 1407-1411, doi:10.1111/dme.12235 (2013).
436 Yu, D. & Simmons, D. Association between blood pressure and risk of cardiovascular hospital admissions among people with type 2 diabetes. *Heart* **100**, 1444-1449, doi:10.1136/heartjnl-2013-304799 (2014).
437 Yun, J. S., Park, Y. M., Cha, S. A., Ahn, Y. B. & Ko, S. H. Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes. *Cardiovasc Diabetol* **17**, 109, doi:10.1186/s12933-018-0752-6 (2018).
438 Zafrir, B. *et al.* Low cardiorespiratory fitness and coronary artery calcification: Complementary cardiovascular risk predictors in asymptomatic type 2 diabetics. *Atherosclerosis* **241**, 634-640, doi:10.1016/j.atherosclerosis.2015.06.020 (2015).
439 Zafrir, B. *et al.* Resting heart rate and measures of effort-related cardiac autonomic dysfunction predict cardiovascular events in asymptomatic type 2 diabetes. *Eur J Prev Cardiol* **23**, 1298-1306, doi:10.1177/2047487315624747 (2016).
440 Zethelius, B. *et al.* A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). *Diabetes Res Clin Pract* **93**, 276-284, doi:10.1016/j.diabres.2011.05.037 (2011).
441 Zhang, C. *et al.* Genetic variation in the hepatic lipase gene and the risk of coronary heart disease among US diabetic men: potential interaction with obesity. *Diabetologia* **49**, 1552-1559, doi:10.1007/s00125-006-0235-2 (2006).
442 Zhang, X. L. *et al.* Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22). *Diabetes Therapy* **11**, 885-903, doi:10.1007/s13300-020-00782-5 (2020).

443 Zhao, Q. *et al.* Impacts of triglyceride-glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment elevation acute coronary syndrome: results from an observational cohort study in China. *Cardiovasc Diabetol* **19**, 108, doi:10.1186/s12933-020-01086-5 (2020).
444 Zhou, J. B. *et al.* Prediction of Proliferative Diabetic Retinopathy to Asymptomatic Obstructive Coronary Artery Disease in Chinese Type 2 Diabetes Individuals: An Exploratory Study. *Metab Syndr Relat Disord* **17**, 367-373, doi:10.1089/met.2018.0140 (2019).
445 Zimering, M. B., Anderson, R. J., Ge, L. & Moritz, T. E. Increased plasma basic fibroblast growth factor is associated with coronary heart disease in adult type 2 diabetes mellitus. *Metabolism* **60**, 284-291, doi:10.1016/j.metabol.2010.02.003 (2011).
446 Zimering, M. B., Anderson, R. J., Ge, L., Moritz, T. E. & Duckworth, W. C. Basic fibroblast growth factor predicts cardiovascular disease occurrence in participants from the veterans affairs diabetes trial. *Frontiers in Endocrinology* **4**, doi:10.3389/fendo.2013.00183 (2013).
447 Zobel, E. H. *et al.* Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria. *Diabetologia* **60**, 1883-1891, doi:10.1007/s00125-017-4344-x (2017).
448 Zoppini, G. *et al.* Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: role of kidney dysfunction. *Atherosclerosis* **212**, 287-291, doi:10.1016/j.atherosclerosis.2010.04.035 (2010).
449 Østergaard, H. B. *et al.* Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients. *Diabetes Metab* **45**, 254-260, doi:10.1016/j.diabet.2018.04.006 (2019).
450 Fitipaldi, H. & Franks, P. W. Ethnic, gender and other sociodemographic biases in genome-wide association studies for the most burdensome non-communicable diseases: 2005-2022. *Hum Mol Genet* **32**, 520-532, doi:10.1093/hmg/ddac245 (2023).
451 Misra, S. *et al.* Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. *The Lancet Diabetes & Endocrinology* **9**, 671-680, doi:https://doi.org/10.1016/S2213-8587(21)00208-4 (2021).
452 Romero-Cabrera, J. L., Ankeny, J., Fernández-Montero, A., Kales, S. N. & Smith, D. L. A Systematic Review and Meta-Analysis of Advanced Biomarkers for Predicting Incident Cardiovascular Disease among Asymptomatic Middle-Aged Adults. *International Journal of Molecular Sciences* **23**, 13540 (2022).
453 Chan, J. *et al.* The Joint Asia Diabetes Evaluation (JADE) Program: a web-based program to translate evidence to clinical practice in Type 2 diabetes. *Diabet Med* **26**, 693-699, doi:10.1111/j.1464-5491.2009.02751.x (2009).
454 Chan, J. C. N. *et al.* Effect of a Web-Based Management Guide on Risk Factors in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A JADE Randomized Clinical Trial. *JAMA Netw Open* **5**, e223862, doi:10.1001/jamanetworkopen.2022.3862 (2022).
455 Lim, L. L. *et al.* Association of technologically assisted integrated care with clinical outcomes in type 2 diabetes in Hong Kong using the prospective JADE Program: A retrospective cohort analysis. *PLoS Med* **17**, e1003367, doi:10.1371/journal.pmed.1003367 (2020).

456 Chan, J. C. *et al.* Effects of telephone-based peer support in patients with type 2 diabetes mellitus receiving integrated care: a randomized clinical trial. *JAMA Intern Med* **174**, 972-981, doi:10.1001/jamainternmed.2014.655 (2014).

457 Lim, L. L. *et al.* Effects of a Technology-Assisted Integrated Diabetes Care Program on Cardiometabolic Risk Factors Among Patients With Type 2 Diabetes in the Asia-Pacific Region: The JADE Program Randomized Clinical Trial. *JAMA Netw Open* **4**, e217557, doi:10.1001/jamanetworkopen.2021.7557 (2021).